# Chapter 17: Schizophrenia

# Chapter X: The Biological and Neurological Basis of Schizophrenia

## Introduction

Schizophrenia is a severe and often chronic mental disorder that profoundly impacts cognition, affect, and social functioning (Groisman & Seminatore, 2003). Affecting approximately 1% of the population worldwide, its onset typically occurs in late adolescence or early adulthood, a critical period for psychosocial development (Buckley & Foster, 2014; Selwood, 2015; Stringer et al., 2015). While the clinical presentation is defined by a constellation of symptoms, the underlying etiology of schizophrenia is increasingly understood as a disorder of the brain, rooted in a complex interplay of genetic predispositions, neurodevelopmental disturbances, and neurochemical imbalances (Dodd, 2007; Tandon et al., 2008b). This chapter aims to provide a comprehensive overview of the biological and neurological basis of schizophrenia, synthesizing evidence from neuropharmacology, genetics, neuroimaging, and developmental neurobiology.

The symptomatology of schizophrenia is classically divided into "positive" and "negative" domains (Buckley & Foster, 2014; Dodd, 2007; Le Lievre et al., 2011). Positive symptoms represent an excess or distortion of normal functions and include phenomena such as delusions (fixed false beliefs), hallucinations (perceptions without external stimuli), and disorganized thought and speech (Buckley & Foster, 2014; Liddle, 1987; Stringer et al., 2015). Conversely, negative symptoms reflect a diminution or loss of normal functions (Andreasen, 1982; Buckley & Foster, 2014; Liddle, 1987). These include affective flattening (reduced emotional expression), alogia (poverty of speech), avolition (lack of motivation), anhedonia (inability to experience pleasure), and asociality (social withdrawal) (Andreasen, 1982; Dodd, 2007; Stănculete & Căpățînă, 2021; Le Lievre et al., 2011). While positive symptoms are often the most dramatic and are correlated with acute episodes and hospitalizations (Liddle, 1987; Fenton, 1991), it is the persistent negative symptoms and associated cognitive deficits that are most closely linked to long-term functional impairment and poor quality of life (Tamminga et al., 1998; Harvey, 2010; McGlashan, 1992).

The understanding of schizophrenia has evolved from a purely psychological construct to a neurodevelopmental disorder of the brain (Groisman & Seminatore, 2003; Stringer et al., 2015). This perspective is supported by a wealth of evidence pointing to genetic heritability, subtle premorbid developmental delays, structural and functional brain abnormalities, and altered neurotransmitter systems (Dodd, 2007; Remschmidt & Schulz, 1994). The "two-hit" or "multiple-hit" hypothesis has gained strong support, positing that a genetic predisposition interacts with environmental or developmental insults (such as perinatal complications or later life stressors) to trigger the manifestation of the illness (Dodd, 2007; Birley & Brown, 1970). This model helps to explain the typical onset in late adolescence, a period of significant synaptic pruning and brain maturation, suggesting that an early developmental vulnerability may only become clinically apparent when the brain undergoes these later organizational changes (Sommer & Arango, 2017).

This chapter will delve into these biological mechanisms in detail. We will first explore the major neurotransmitter systems implicated in the disorder, with a particular focus on the dopamine hypothesis and its refinements. Subsequently, we will examine the genetic architecture of schizophrenia, discussing heritability, candidate genes, and molecular pathways. The discussion will then shift to the macroscopic level, reviewing structural and functional neuroimaging findings that have identified abnormalities in specific brain regions and neural circuits. Following this, we will consider the neurodevelopmental trajectory of the illness, from premorbid signs to the prodromal phase and the onset of the first psychotic episode. Finally, we will connect these biological findings to the mechanisms of current treatments and discuss the implications for future therapeutic strategies, acknowledging the significant heterogeneity of the disorder and the ongoing quest to identify distinct biological subtypes.

## Neurobiological Systems

The search for the biological underpinnings of schizophrenia has centered on the brain's complex signaling networks, with neurotransmitter systems being a primary focus of investigation for decades. The discovery that certain drugs could induce or alleviate psychotic symptoms provided the foundational clues that have guided neuropharmacological research and led to the development of dominant neurochemical theories of the disorder (Dodd, 2007).

### The Dopamine Hypothesis

The cornerstone of schizophrenia neuropharmacology is the dopamine hypothesis, which in its simplest form posits that psychotic symptoms arise from an excess of dopaminergic activity (Dodd, 2007). This theory emerged from several key observations. First, drugs that increase dopamine release, such as amphetamine and cocaine, can induce psychotic symptoms in healthy individuals that are phenomenologically similar to the positive symptoms of schizophrenia (Dodd, 2007). Second, and most critically, the therapeutic efficacy of first-generation "typical" antipsychotic medications, such as chlorpromazine and haloperidol, was found to be directly correlated with their ability to block dopamine D2 receptors (Dodd, 2007). Positron Emission Tomography (PET) studies have confirmed that a D2 receptor occupancy of approximately 78% is associated with the clinical efficacy of these typical antipsychotics (Dodd, 2007).

Further imaging research has refined this hypothesis, suggesting a more nuanced picture of dopamine dysregulation. Rather than a simple global excess, evidence points to a model of regional dopamine imbalance (Abi‐Dargham et al., 2009). This revised model proposes hyperactivity of the mesolimbic dopamine pathway, which projects from the ventral tegmental area to the nucleus accumbens and other limbic structures. This hyperactivity is thought to be the primary driver of positive symptoms like delusions and hallucinations (Dodd, 2007; Abi‐Dargham et al., 2009). Postmortem studies have found increased dopamine or its metabolite, homovanillic acid, in limbic areas and the left amygdala of patients with schizophrenia, although this finding may be a consequence of long-term antipsychotic treatment (Dodd, 2007).

In contrast, the negative and cognitive symptoms of schizophrenia are hypothesized to be associated with a deficit in dopamine function, or hypoactivity, in the mesocortical pathway, which projects to the prefrontal cortex (PFC) (Dodd, 2007; Stringer et al., 2015). This "hypofrontality," or reduced frontal lobe function, is a consistent finding in functional neuroimaging studies and is strongly linked to negative symptoms and neurocognitive deficits (Dodd, 2007; Fletcher, 2003). This dual-pathway model helps to explain why typical antipsychotics, which block D2 receptors globally, are effective against positive symptoms but may have little effect on or even worsen negative and cognitive symptoms (Dodd, 2007; Abi‐Dargham et al., 2009).

Five main types of dopamine receptors (D1-D5) have been identified, each with a distinct distribution in the brain. D1 and D2 receptors are found in high concentrations in the cerebral cortex and basal ganglia (striatum), respectively (Dodd, 2007). D3 and D4 receptors are concentrated in the limbic system, while D5 receptors are located in the thalamus, hippocampus, and hypothalamus (Dodd, 2007). The hyperactivity of the dopamine system, particularly involving the D2 receptor, is considered most important for the positive symptoms of schizophrenia (Dodd, 2007).

### Serotonin, Glutamate, and GABA Systems

While dopamine dysregulation remains central, it is clear that other neurotransmitter systems are also involved, either primarily or through their interaction with dopamine pathways (Dodd, 2007). The serotonin (5-HT) system has received considerable attention, largely due to the pharmacology of "atypical" or second-generation antipsychotics. These agents, such as clozapine and risperidone, are not only D2 receptor antagonists but also potent antagonists at serotonin 5-HT2A receptors (Dodd, 2007). This dual action is thought to contribute to their broader efficacy, including potential benefits for negative symptoms, and their lower propensity to cause extrapyramidal side effects compared to typical antipsychotics (Dodd, 2007). Some theories suggest that serotonin hyperactivity may be a feature of schizophrenia (Dodd, 2007), and that blocking 5-HT2A receptors may modulate dopamine release in both the striatum and the cortex, thereby helping to correct the regional imbalances. Furthermore, the ability of hallucinogenic drugs like LSD, which are serotonin agonists, to produce psychotic phenomena provides additional evidence for the involvement of this system (Rinkel et al., 1952; Cole & Katz, 1964).

The glutamate system, the primary excitatory neurotransmitter system in the brain, has also been implicated. The glutamate hypothesis of schizophrenia was spurred by observations that antagonists of the N-methyl-D-aspartate (NMDA) glutamate receptor, such as phencyclidine (PCP) and ketamine, can induce a state that mimics both the positive and negative symptoms of schizophrenia more closely than dopamine agonists (Sommer & Arango, 2017). This has led to the theory that schizophrenia may involve hypofunction of NMDA receptors, potentially leading to downstream effects on dopamine and other systems (Sommer & Arango, 2017). Reduced NMDA receptor activity has been proposed as a key neurobiological deviation in the early phases of the illness (Sommer & Arango, 2017).

Finally, the gamma-aminobutyric acid (GABA) system, the brain's main inhibitory neurotransmitter system, is also believed to be dysfunctional in schizophrenia (Dodd, 2007). GABAergic interneurons play a critical role in regulating cortical activity and synchronizing neural oscillations, which are essential for cognitive processes like working memory (Schwartz, 1990). Postmortem studies have suggested a loss of GABAergic neurons in the hippocampus of individuals with schizophrenia (Dodd, 2007). Decreased GABAergic inhibition, particularly from chandelier cells, could lead to disinhibition of pyramidal neurons and cortical hyperexcitability, contributing to both cognitive deficits and psychotic symptoms (Sommer & Arango, 2017; Schwartz, 1990). A hypothesised loss of GABAergic neurons in the hippocampus could lead to increased dopamine activity, linking the two systems (Dodd, 2007). The interplay between these systems—dopamine, serotonin, glutamate, and GABA—is exceedingly complex, and it is likely that the pathophysiology of schizophrenia involves a disruption in the delicate balance between them rather than a deficit in a single transmitter (Dodd, 2007; Sommer & Arango, 2017).

## Genetic and Molecular Basis

Schizophrenia is widely recognized as a highly heritable disorder, with genetic factors playing a substantial role in its etiology (Buckley & Foster, 2014; Dodd, 2007). While environmental factors are critical for triggering the illness, the underlying vulnerability is largely genetic (Meehl, 1989; Tandon et al., 2008b). Understanding the genetic architecture of schizophrenia is crucial for elucidating its molecular pathophysiology and developing novel therapeutic strategies.

### Heritability and Familial Risk

The evidence for a strong genetic component in schizophrenia comes primarily from family, twin, and adoption studies (Dodd, 2007). These studies consistently demonstrate that the risk of developing schizophrenia increases with the degree of genetic relatedness to an affected individual (Cadoret & Winokur, 1972). While the lifetime prevalence in the general population is approximately 1% (Selwood, 2015), the risk for a sibling of a person with schizophrenia is about 10% (Dodd, 2007). For a child with one parent with schizophrenia, the risk is approximately 6%, but this figure rises dramatically to 46% if both parents have the disorder (Dodd, 2007).

Twin studies provide the most compelling evidence for heritability. The concordance rate for monozygotic (identical) twins, who share 100% of their genes, is nearly 50% (Dodd, 2007). In contrast, the concordance rate for dizygotic (fraternal) twins, who share on average 50% of their genes, is about 17% (Dodd, 2007). This marked difference highlights a strong genetic influence. However, the fact that the concordance rate for identical twins is not 100% unequivocally demonstrates that genetic factors alone are not sufficient to cause the illness; non-genetic or environmental factors must also play a crucial role (Dodd, 2007; Tandon et al., 2008b). This understanding forms the basis of the diathesis-stress or "multiple-hit" models, which propose that a genetic predisposition requires subsequent environmental insults to manifest as clinical illness (Dodd, 2007; Meehl, 1989).

### Candidate Genes and Molecular Mechanisms

The search for specific genes that confer risk for schizophrenia has been a monumental challenge due to the disorder's complex and likely polygenic nature (Dodd, 2007; Stringer et al., 2015). It is now widely accepted that schizophrenia is not caused by a single gene but rather by the combined effects of many genes of small effect, possibly interacting with each other and with environmental factors (Meehl, 1989; Stringer et al., 2015).

Early linkage studies identified multiple chromosomal regions that may harbor susceptibility genes for schizophrenia. These include loci on chromosomes 3p, 5q, 6p, 6q, 8p, 10p, 13q, 15q, 18p, and 22q (Dodd, 2007). The 22q11.2 deletion syndrome (velocardiofacial syndrome), for instance, is a known risk factor, with affected individuals showing a significantly increased rate of psychotic disorders (Sommer & Arango, 2017).

More recent genome-wide association studies (GWAS) have begun to identify specific common genetic variants associated with schizophrenia, although each variant contributes only a very small amount to the overall risk (Stringer et al., 2015). These studies have implicated genes involved in several key neurobiological processes, reinforcing theories derived from other areas of research. For example, genes related to the dopamine D2 receptor, the glutamate system (including NMDA receptors), and GABAergic signaling have been identified as plausible candidates (Dodd, 2007; Sommer & Arango, 2017).

Other molecular mechanisms have also been proposed. For instance, large trinucleotide repeats, specifically CAG/CTG repeats on chromosomes 17 and 18, have been implicated in some studies, suggesting a potential link to mechanisms seen in other neurodegenerative disorders like Huntington's disease (Dodd, 2007).

The heterogeneity of the disorder poses a significant obstacle to genetic research (Carpenter & Kirkpatrick, 1988). Different combinations of risk genes may lead to different clinical presentations or subtypes of schizophrenia (Stringer et al., 2015). For example, some genetic profiles might confer a higher risk for prominent negative symptoms, while others might predispose individuals to severe cognitive deficits or a more aggressive course of illness (Fenton, 1991). The ongoing effort to link specific genetic variants to distinct clinical phenotypes, neurobiological markers, or treatment responses is a critical area of future research that holds the promise of personalized medicine in psychiatry.

## Brain Structure and Function

The conceptualization of schizophrenia as a brain disorder is strongly supported by a large and growing body of neuroimaging research. Both structural and functional imaging techniques have consistently revealed a range of abnormalities in brain anatomy and activity in individuals with schizophrenia compared to healthy controls. These findings, while not diagnostic on an individual level, provide crucial insights into the neural circuits and systems that are disrupted in the disorder (Dodd, 2007).

### Structural Neuroimaging Findings

Structural magnetic resonance imaging (MRI) has been instrumental in identifying subtle but consistent neuroanatomical differences in schizophrenia. One of the most replicated findings is ventricular enlargement, particularly of the lateral and third ventricles (Dodd, 2007). This enlargement is thought to be a proxy for a reduction in surrounding brain tissue volume. Indeed, studies have documented selective reductions in the size of several key brain regions.

The frontal lobes, which are critical for executive functions, planning, and regulation of behavior, are frequently implicated (Dodd, 2007; Jurado & Junqué, 2001). A decrease in the volume of the frontal lobe, along with sulcal widening in frontal and temporal areas, is a common finding (Dodd, 2007). This structural deficit is believed to be a key neural substrate for the negative symptoms and cognitive impairments characteristic of the disorder (Tamminga et al., 1998). Some studies also indicate a small but significant difference in overall brain and intracranial volume in patients with schizophrenia (Dodd, 2007).

The limbic system, which is central to emotion and memory, also shows structural abnormalities. Reductions in the volume of medial temporal lobe structures, including the hippocampus and amygdala, have been consistently reported (Dodd, 2007). Given the hippocampus's role in memory and the amygdala's role in emotional processing, these findings are highly relevant to the cognitive and affective disturbances seen in schizophrenia (Dodd, 2007; Abi‐Dargham et al., 2009).

Other subcortical structures are also affected. The thalamus, a critical relay station for sensory information and a key node in cortico-striato-thalamo-cortical loops, has been found to be reduced in size (Dodd, 2007). Similarly, the basal ganglia, including the striatum, show volume alterations, although these can be confounded by the effects of long-term antipsychotic medication (Dodd, 2007). Some studies have also pointed to abnormalities in the cerebellum, a structure traditionally associated with motor control but now known to be involved in cognitive and affective functions (Dodd, 2007).

In addition to volume reductions, other subtle structural anomalies suggest a neurodevelopmental origin. An increased incidence of cavum septum pellucidum and partial agenesis of the corpus callosum has been reported, pointing to potential disruptions in early brain development (Dodd, 2007). These findings, coupled with the observation that many of these structural changes are present at the first episode of psychosis and do not appear to progress substantially over time in most patients, support the view of schizophrenia as a disorder of brain development rather than a purely neurodegenerative process (Stringer et al., 2015; McGlashan, 1992).

### Functional Neuroimaging Findings

Functional neuroimaging techniques, such as positron emission tomography (PET) and functional MRI (fMRI), have allowed researchers to investigate brain activity during rest and while performing cognitive tasks. A cardinal finding from these studies is "hypofrontality," which refers to reduced baseline activity or diminished activation of the frontal cortex, particularly the dorsolateral prefrontal cortex (DLPFC), during tasks that require executive functions like working memory (Dodd, 2007; Fletcher, 2003). This functional impairment is strongly correlated with the severity of negative symptoms and cognitive deficits (Dodd, 2007; Fletcher, 2003; Tamminga et al., 1998).

PET studies have implicated a distributed network of brain regions in the pathophysiology of schizophrenia. Beyond the frontal cortex (orbital, dorsolateral, medial), abnormal activity has been observed in the anterior cingulate gyrus, thalamus, several temporal lobe subregions, and the cerebellum (Dodd, 2007). This suggests that schizophrenia is not a disorder of a single brain region but rather a disruption of large-scale neural circuits and their connectivity (Anticevic et al., 2013).

Functional imaging has also provided insights into the neural basis of specific symptoms. For example, auditory hallucinations have been linked to spontaneous activity in auditory processing areas of the temporal lobe, such as Heschl's gyrus (Jiménez De La Peña et al., 2018), suggesting that patients may be misattributing internally generated neural signals as external voices. Similarly, PET studies have begun to identify the anatomic substrate for visual hallucinations, implicating a network involving the inferotemporal cortex (responsible for visual recognition), the basal ganglia, and the thalamus (Dodd, 2007). Increased dopaminergic activity in the basal ganglia is thought to disrupt visual processing via this circuit, leading to altered visual perceptions (Dodd, 2007).

These structural and functional findings provide a compelling neurobiological framework for understanding the diverse symptoms of schizophrenia. The evidence points towards a widespread dysconnectivity, particularly affecting fronto-temporal and fronto-limbic circuits, which disrupts the integration of thought, emotion, and perception that is fundamental to normal mental life.

## Developmental Neurobiology

The clinical onset of schizophrenia typically occurs in late adolescence or early adulthood, but a growing body of evidence indicates that its roots lie much earlier in development (Groisman & Seminatore, 2003; Remschmidt & Schulz, 1994). The neurodevelopmental hypothesis of schizophrenia posits that a combination of genetic susceptibility and early environmental insults disrupts normal brain maturation, creating a static brain lesion or vulnerability that remains clinically silent for many years (Stringer et al., 2015; Meehl, 1989). The overt symptoms of the disorder are thought to emerge only when later maturational processes, such as synaptic pruning and myelination during adolescence, unmask this latent vulnerability (Sommer & Arango, 2017).

### Early Life and Premorbid Signs

Evidence for early developmental disruption comes from multiple lines of research. Retrospective and prospective studies have linked schizophrenia to a higher incidence of perinatal complications, such as birth injuries and fetal hypoxia (Dodd, 2007; Groisman & Seminatore, 2003). These events are thought to act as "second hits" that interact with a genetic predisposition to alter the trajectory of brain development (Dodd, 2007). Epidemiological findings, such as the increased rate of schizophrenia among individuals born in the winter or early spring, have been speculatively linked to maternal exposure to viral infections (e.g., influenza) during the second trimester of gestation, a critical period for neuronal migration and cortical organization (Dodd, 2007; Groisman & Seminatore, 2003).

Long before the onset of psychosis, many individuals who later develop schizophrenia exhibit subtle premorbid abnormalities in development and functioning (Remschmidt & Schulz, 1994; Loranger, 1984). These can include delays in reaching motor milestones, such as walking, as well as cognitive, language, and communication delays (Groisman & Seminatore, 2003; Sommer & Arango, 2017). Socially, these children may show signs of withdrawal, shyness, or have fewer friends (Alderton, 1966; Sommer & Arango, 2017). Some studies have noted a history of schizoid or schizotypal personality traits in up to 25% of individuals who develop schizophrenia (Dodd, 2007; Tantam, 1988). These early signs are often non-specific and are not predictive on an individual basis, but they collectively point to a deviation from the normal neurodevelopmental path years before the illness becomes clinically manifest (Remschmidt & Schulz, 1994; Addington, 2013). Neurological soft signs, which are minor, non-localizable neurological abnormalities, are also more common in individuals with schizophrenia and their relatives, further supporting an early CNS disruption (Arango et al., 2000).

### The Prodromal Phase

As adolescence progresses, these subtle premorbid difficulties often intensify and evolve into a more distinct prodromal phase, which can last from months to several years before the first full-blown psychotic episode (Stringer et al., 2015; Schultze‐Lutter, 2016). This period is characterized by a decline in social and occupational or academic functioning (Yung, 2011; Pereira, 2021). The symptoms are often non-specific and can include anxiety, depression, irritability, sleep disturbances, and social withdrawal (Schultze‐Lutter, 2016; Triki et al., 2012).

A key development during the prodrome is the emergence of subclinical or "attenuated" psychotic symptoms (Yung, 2011; Addington, 2013). These are experiences that resemble the positive symptoms of schizophrenia but are less severe, less frequent, or are accompanied by a greater degree of insight (Schultze‐Lutter, 2016). Examples include unusual thought content, suspiciousness, and perceptual aberrations (Yung, 2011). Another set of prodromal indicators are "basic symptoms," which are subtle, subjectively experienced disturbances in mental processes like thinking, perception, and stress tolerance, which are experienced with full insight (Schultze‐Lutter, 2016; Schultze‐Lutter & Theodoridou, 2017). The presence of these attenuated psychotic and basic symptoms, combined with a decline in functioning, defines the "ultra-high-risk" (UHR) or "clinical high-risk" (CHR) state for psychosis (Yung, 2011; Addington, 2013). Individuals meeting UHR criteria have a significantly elevated risk of transitioning to a full psychotic disorder, often within 1-2 years (Addington, 2013).

The prodromal period is a critical window of opportunity for early detection and intervention (Salokangas & McGlashan, 2008). Research in this phase aims to identify reliable clinical and biological predictors of transition to psychosis to allow for targeted preventive strategies (Addington, 2013). Cognitive decline, particularly in executive functions and memory, has been identified as one of the clearest predictors of transition, alongside the severity of subclinical psychotic symptoms (Sommer & Arango, 2017). This developmental perspective underscores that schizophrenia is not a disease with a sudden, inexplicable onset, but rather the culmination of a long-term pathological process that begins early in life and unfolds across critical developmental stages.

## Treatment Mechanisms

The biological understanding of schizophrenia has directly informed the development and mechanism of action of its primary pharmacological treatments: antipsychotic medications. These agents work by modulating the neurotransmitter systems implicated in the disorder's pathophysiology, providing symptomatic relief and helping to prevent relapse (Dodd, 2007; Carvajal, 2004).

### Antipsychotic Medications: Dopamine D2 Receptor Blockade

The mainstay of treatment for schizophrenia for over half a century has been antipsychotic drugs that act as antagonists at the dopamine D2 receptor (Dodd, 2007). The first-generation, or "typical," antipsychotics, such as chlorpromazine and haloperidol, derive their efficacy almost exclusively from this mechanism (Dodd, 2007). Their ability to reduce positive symptoms like hallucinations and delusions is directly proportional to their affinity for and blockade of D2 receptors in the mesolimbic pathway (Dodd, 2007; Abi‐Dargham et al., 2009). As established by PET imaging, achieving approximately 70-80% occupancy of striatal D2 receptors is generally required for a therapeutic effect (Dodd, 2007).

However, this widespread D2 blockade is not without consequences. Blockade of D2 receptors in the nigrostriatal pathway, a circuit crucial for motor control, leads to extrapyramidal symptoms (EPS), including parkinsonism (bradykinesia, rigidity, tremor), dystonia, and akathisia (Dodd, 2007; Montes & Rey, 2009). Long-term blockade can also lead to tardive dyskinesia (TD), a potentially irreversible movement disorder characterized by involuntary choreoathetoid movements, particularly of the orofacial region (Klawans et al., 1984; Sharma, 2009). Furthermore, by blocking dopamine in the mesocortical pathway, where dopamine activity may already be deficient, typical antipsychotics can sometimes worsen negative and cognitive symptoms (Dodd, 2007).

### Atypical Antipsychotics: Broader Receptor Profiles

The development of second-generation, or "atypical," antipsychotics in the 1990s marked a significant advance in the treatment of schizophrenia (Montes & Rey, 2009). The prototype of this class, clozapine, demonstrated superior efficacy in treatment-resistant schizophrenia and a much lower risk of EPS and TD (Dodd, 2007; Ayala et al., 2017). This improved profile is attributed to its complex pharmacology. Atypical antipsychotics, including risperidone, olanzapine, and quetiapine, are characterized by a combination of D2 receptor antagonism and potent serotonin 5-HT2A receptor antagonism (Dodd, 2007; Montes & Rey, 2009).

The "serotonin-dopamine antagonist" model proposes that 5-HT2A blockade can increase dopamine release in certain brain regions, including the nigrostriatal and mesocortical pathways. This may counteract the motor side effects of D2 blockade in the striatum and potentially improve negative and cognitive symptoms by enhancing dopamine function in the prefrontal cortex (Dodd, 2007). PET studies have shown that atypical agents achieve their clinical effect at a lower D2 receptor occupancy (around 40-60%) compared to typicals, which may also contribute to their better motor side effect profile (Dodd, 2007).

In addition to D2 and 5-HT2A antagonism, many atypical antipsychotics have activity at a wide range of other receptors, including other dopamine and serotonin subtypes, as well as adrenergic, histaminergic, and muscarinic receptors (Montes & Rey, 2009). This broad receptor-binding profile likely contributes to both their therapeutic effects and their distinct side-effect profiles, which include metabolic issues such as weight gain, hyperglycemia, and hyperlipidemia (Montes & Rey, 2009). Aripiprazole represents a further evolution, acting as a partial agonist at D2 receptors. This mechanism allows it to function as a "dopamine system stabilizer," reducing dopaminergic tone in the hyperactive mesolimbic pathway while potentially increasing it in the hypoactive mesocortical pathway (Dodd, 2007).

### Beyond Antipsychotics

While antipsychotics are the cornerstone of treatment, other biological interventions may be used adjunctively. Electroconvulsive therapy (ECT) is not typically a first-line treatment for schizophrenia but can be effective for catatonic presentations or for severe, treatment-resistant psychotic or affective symptoms (Dodd, 2007; Fink, 2010). Mood stabilizers, antidepressants, and benzodiazepines may also be beneficial for managing comorbid mood symptoms, anxiety, or agitation (Dodd, 2007; Carvajal, 2004). Antidepressants, in particular, have been explored as a strategy to address negative symptoms, although their efficacy for primary negative symptoms, as distinct from secondary depression, is modest at best (Barnes & Paton, 2011; Singh et al., 2009).

The ultimate goal of treatment is not just symptom remission but functional recovery (Harvey, 2010). Therefore, pharmacological treatments are most effective when integrated with psychosocial interventions, such as cognitive-behavioral therapy, family therapy, and vocational rehabilitation, which address the functional, social, and psychological consequences of the illness (Dodd, 2007; Lewis et al., 2005).

## Future Directions

Despite significant advances in understanding the biological basis of schizophrenia, the disorder remains a formidable clinical and scientific challenge. The heterogeneity of its clinical presentation, course, and treatment response suggests that "schizophrenia" is likely an umbrella term for several distinct pathophysiological processes that converge on a similar clinical syndrome (Carpenter & Kirkpatrick, 1988; Stringer et al., 2015). Future research must prioritize dissecting this heterogeneity to pave the way for more precise diagnostics and personalized treatments.

A major goal is the identification of reliable biomarkers that can aid in early diagnosis, predict treatment response, and stratify patients into more homogeneous neurobiological subtypes (Addington, 2013). This endeavor will require the integration of data across multiple levels of analysis, from genetics and molecular biology to neuroimaging and clinical phenomenology. For example, linking specific genetic risk variants to particular patterns of brain connectivity, cognitive deficits, or symptom profiles could help to deconstruct the "schizophrenia" label into more biologically meaningful entities (Stringer et al., 2015). Large-scale, longitudinal studies of individuals at clinical high risk for psychosis are essential for identifying biomarkers that predict the transition to illness and for understanding the neurobiological changes that occur during this critical period (Addington, 2013; Salokangas & McGlashan, 2008). Advances in magnetic resonance spectroscopy to measure in vivo concentrations of neurotransmitters like glutamate and GABA, or markers of oxidative stress like glutathione, offer promising avenues for testing specific neurochemical hypotheses in high-risk populations (Sommer & Arango, 2017).

The development of novel therapeutics is another critical frontier. Current antipsychotic medications, while effective for positive symptoms, are limited by their side-effect profiles and their modest impact on the negative and cognitive symptoms that drive long-term disability (Tamminga et al., 1998). The growing understanding of non-dopaminergic systems offers new targets for drug development. For instance, agents that modulate the NMDA glutamate receptor or enhance GABAergic signaling are under active investigation as potential treatments for cognitive and negative symptoms (Sommer & Arango, 2017). Similarly, anti-inflammatory agents and antioxidants (e.g., N-acetylcysteine to restore glutathione function) are being explored as interventions that could target the neuroinflammatory and oxidative stress pathways implicated in the illness (Sommer & Arango, 2017).

Furthermore, the field is moving beyond a purely pharmacological approach to embrace interventions that can directly target and modify dysfunctional neural circuits. Non-invasive brain stimulation techniques, such as repetitive transcranial magnetic stimulation (rTMS), show promise for modulating activity in specific cortical regions, such as the prefrontal cortex, to improve negative symptoms or cognitive deficits (Walther, 2018). Cognitive remediation, a form of intensive cognitive training, aims to improve neurocognitive deficits by harnessing principles of neuroplasticity (Lewis et al., 2005). Combining these targeted interventions with psychosocial therapies like social recovery therapy (SRT) may offer a synergistic approach to promoting not just symptom remission, but true functional recovery (Fowler, 2024).

Finally, a deeper integration of phenomenological and neurobiological approaches is needed. Understanding the subjective experience of schizophrenia, including disturbances of the core self or "ipseity," can provide crucial insights into the fundamental nature of the disorder and guide neuroscientific inquiry (Sass et al., 2018; Nelson & Sass, 2018). By linking these "anomalous self-experiences" to specific patterns of brain activity or connectivity, researchers may uncover the neural basis of the profound disruption in the sense of self that lies at the heart of schizophrenia (Sass et al., 2018). This integrated bio-pheno-social model is essential for moving beyond a symptom-based classification and toward a mechanistic understanding that can truly transform patient care.

## Conclusion

Schizophrenia is a complex and devastating disorder of the brain, the biological basis of which is gradually being unraveled through decades of intensive research. The evidence overwhelmingly points to a neurodevelopmental etiology, in which a strong genetic vulnerability interacts with early environmental factors to disrupt the normal trajectory of brain maturation (Groisman & Seminatore, 2003; Tandon et al., 2008b). This process results in a cascade of neurobiological abnormalities that ultimately manifest in the profound disturbances of thought, perception, emotion, and motivation that define the clinical syndrome.

At the neurochemical level, the dopamine hypothesis remains a central organizing principle, particularly in explaining positive symptoms and the mechanism of antipsychotic action (Dodd, 2007; Abi‐Dargham et al., 2009). However, it is now clear that this is an oversimplification. A more comprehensive model must incorporate the roles of glutamate hypofunction, GABAergic inhibitory deficits, and serotonergic dysregulation, all of which are intricately interconnected with the dopamine system (Dodd, 2007; Sommer & Arango, 2017). These widespread neurochemical imbalances are reflected at the systems level as structural and functional abnormalities in a distributed network of brain regions. Neuroimaging has consistently identified reduced volumes in frontal and temporal lobes, the hippocampus, and thalamus, coupled with ventricular enlargement (Dodd, 2007). Functionally, hypofrontality during cognitive tasks and aberrant connectivity within and between large-scale brain networks are key findings that correlate with the negative and cognitive symptoms that are the primary drivers of long-term disability (Fletcher, 2003; Tamminga et al., 1998).

The developmental course of the illness, from subtle premorbid signs in childhood through a distinct prodromal phase in adolescence, provides a temporal map of this unfolding neuropathology (Yung, 2011; Schultze‐Lutter, 2016). This long pre-psychotic period underscores the importance of early detection and intervention, a major focus of current research aimed at altering the course of the illness before significant functional decline occurs (Salokangas & McGlashan, 2008).

While our understanding has advanced considerably, significant challenges remain. The profound heterogeneity of schizophrenia at every level—from genetics to clinical presentation and outcome—is a major obstacle (Carpenter & Kirkpatrick, 1988; Stringer et al., 2015). The current diagnostic category likely encompasses multiple distinct disease processes. Future progress will depend on our ability to parse this heterogeneity using biological markers to define more valid, mechanistically-based subtypes. This will be essential for developing targeted, personalized treatments that go beyond the current one-size-fits-all approach and address the full spectrum of the disorder's disabling symptoms, particularly the persistent negative and cognitive deficits. The integration of genetic, neuroimaging, cognitive, and phenomenological data within a developmental framework offers the most promising path toward a truly comprehensive biological understanding of schizophrenia and, ultimately, a transformation in its treatment and prevention.


## References

1. Abdelsayed, S., Acevedo, R., & Clemow, L. (2017). Is sleep deprivation associated with behavioral changes in children and adolescents?. Evidence-Based Practice. https://doi.org/10.1097/01.ebp.0000541629.93211.cb
2. Abi‐Dargham, A., Slifstein, M., Kegeles, L., & Laruelle, M. (2009). 10.1 Dopamine Dysfunction in Schizophrenia. Oxford University Press eBooks. https://doi.org/10.1093/acprof:oso/9780195373035.003.0036
3. Abi‐Jaoude, E., Stall, N. M., & Rochon, P. A. (2018). Psychotropic drugs for the behavioural and psychological symptoms of dementia: no free ride. Canadian Medical Association Journal. https://doi.org/10.1503/cmaj.181486
4. Addington, J. (2013). Identifying a Treatable Psychosis-Risk Cohort. The Canadian Journal of Psychiatry. https://doi.org/10.1177/070674371305800102
5. Ademi, L. A., & Ademi, B. (2017). EVALUATION AND MANAGEMENT OF A CHILD WITH FEBRILE SEIZURE.
6. Agustini, B., Bocharova, M., Young, A. H., & Juruena, M. F. (2017). Seasonal Affective Disorder and HPA axis function: A Systematic Review.. Frontiers in Psychiatry. https://doi.org/10.3389/conf.fpsyt.2017.48.00036
7. Ahemad, M., Ahmad, P. M. F., & Shafaat, M. (2018). Effect of Dalak (Massage) in the Management of Sahar (Insomnia). https://doi.org/10.37591/rrjoush.v5i2.130
8. Ahmadbegi, S., Jafarian, A. A., Aliasl, J., & Rostami, A. (2016). Typical Absence Seizure Similarity to “Shokhous” in Iranian Traditional Medicine. Iranian Red Crescent Medical Journal. https://doi.org/10.5812/ircmj.21048
9. Ajiboye, P., & Yusuf, A. D. (2013). Scientific Letter: Monosymptomatic Hypochondriacal Psychosis (somatic delusional disorder): A report of two cases. African Journal of Psychiatry. https://doi.org/10.4314/ajpsy.v16i2.11
10. Alderton, H. R. (1966). A Review of Schizophrenia in Childhood. Canadian Psychiatric Association Journal. https://doi.org/10.1177/070674376601100403
11. Alexandre, S., Misery, L., Dutray, S., Chastaing, M., Consoli, S.-M., Audra, H., Bauer, D., Bertolus, S., Callot, V., Cardinaud, F., Corrin, E., Féton-Danou, N., Malet, R., Touboul, S., & Consoli, S. (2007). Functional Itch Disorder or Psychogenic Pruritus: Suggested Diagnosis Criteria From the French Psychodermatology Group. Acta Dermato Venereologica. https://doi.org/10.2340/00015555-0266
12. Almannai, M., Dai, H., El‐Hattab, A. W., & Wong, L. C. (2017). FBXL4-Related Encephalomyopathic Mitochondrial DNA Depletion Syndrome.
13. Alvarado, R., Shilling, S., & Jorquera, M. J. (2015). Uso de la Intervención Critical Time Intervention en personas con primer episodio de psicosis. Revista de la Facultad de Ciencias Médicas de Córdoba. https://doi.org/10.31053/1853.0605.v72.n4.13845
14. Andrasik, F., Lipchik, G. L., McCrory, D. C., & Wittrock, D. A. (2005). Outcome Measurement in Behavioral Headache Research: Headache Parameters and Psychosocial Outcomes. Headache The Journal of Head and Face Pain. https://doi.org/10.1111/j.1526-4610.2005.05094.x
15. Andreasen, N. C. (1982). Negative Symptoms in Schizophrenia. Archives of General Psychiatry. https://doi.org/10.1001/archpsyc.1982.04290070020005
16. Andreev, A. (2000). [Differentiated types of chronic agoraphobia].. PubMed.
17. Anticevic, A., Krystal, J. H., & Barch, D. M. (2013). Translational cognitive neuroscience of schizophrenia: bridging neurocognitive and computational approaches toward understanding cognitive deficits. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9781139003872.013
18. Antoniuk, S. A. (2013). [Non-epileptic disorders in infancy and adolescence].. PubMed.
19. Antón, R., Conde, L. A., Gardeazábal, M. B., Ozcariz, P. A., Zariquiey, N. C., Figueiredo, N. D. S., & Salinas, V. F. (2021). Cycloid psychosis. European Psychiatry. https://doi.org/10.1192/j.eurpsy.2021.1702
20. Anuzyte, J. S., Rutkauskaitė, G., & Mameniškienė, R. (2018). Transient epileptic amnesia. Neurologijos seminarai. https://doi.org/10.29014/ns.2018.26
21. Apter, A. (2000). Personality constellations in suicidal behavior. Éditions GREUPP eBooks. https://doi.org/10.3917/greu.isap.2000.01.0263
22. Arango, C., Kirkpatrick, B., & Buchanan, R. W. (2000). Neurological Signs and the Heterogeneity of Schizophrenia. American Journal of Psychiatry. https://doi.org/10.1176/appi.ajp.157.4.560
23. Arenson, C., Busby‐Whitehead, J., Brummel‐Smith, K., O’Brien, J. G., Palmer, M. H., & Reichel, W. (2010). Evaluation and Management of Dementia. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511575952.017
24. Arjun, D., Goel, N., Surinder, S., & Ravi, K. V. (2015). Sudden Sensorineural Hearing Loss; Prognostic Factors.. PubMed.
25. Arredondo-Aldana, K., Mera-Posligua, M. J., & Alencastro, J. A. P. (2021). Trastorno Depresivo Persistente y Trastornos de Ansiedad Generalizada Proveniente de un Estrés Post Traumático Crónico: Presentación de un Caso Clínico. Revista Científica Arbitrada en Investigaciones de la Salud GESTAR. https://doi.org/10.46296/gt.v4i8edesp.0027
26. Arteaga, T. L., Amo, C., González, C. S., & Sánchez, D. H. (2016). Nonconvulsive status epilepticus and psychotic symptoms: case report Stato epilettico non convulsivo e sintomi psicotici: caso clinico.
27. Ayala, L., Gómez‐Revuelta, M., Requena, C. M., Acilu, E. S. D. A. G. D., Olivares, O. P., Ruíz, M. J., Morales, N. N., Martin, M., Zufiaurre, M. L., Hernández, B., Itoiz, A. A., Peña, M., & González‐Pinto, A. (2017). Clozapine: Since the very beginning?. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2017.01.1402
28. Bains, N., Abdijadid, S., & Miller, J. (2021). Major Depressive Disorder (Nursing).
29. Baldwin, D. S., Ajel, K., & Garner, M. (2008). Anxiety disorders. Medicine. https://doi.org/10.1016/j.mpmed.2008.05.002
30. Bano, S., Das, S., Mazumder, A., Das, S., & Aman, S. (2015). The Landau Kleffner Syndrome.
31. Bansal, R., & Sheldon, S. H. (2008). Parasomnias in Childhood. CRC Press eBooks. https://doi.org/10.3109/9781420048087-26
32. Barbosa, M. O. S., Silva, F. L. C., Castro, J. D. O., Marino, L. D. B., Silva, V. D. S., Pinho, R. C., & Bonfim, Y. C. (2018). PROCESSO DE ENFERMAGEM EM PACIENTE COM ESQUIZOFRENIA HEBEFRÊNICA: UM RELATO DE CASO. 13º Congresso Internacional Rede Unida.
33. Barnes, T. R. E., & Paton, C. (2011). Do antidepressants improve negative symptoms in schizophrenia?. BMJ. https://doi.org/10.1136/bmj.d3371
34. Bd, S. (1990). Early information processing in schizophrenia.. Psychiatric medicine.
35. Beauchaine, T. P., & Bell, Z. (2018). Respiratory Sinus Arrhythmia as a Transdiagnostic Biomarker of Emotion Dysregulation. https://doi.org/10.1093/oxfordhb/9780190689285.013.12
36. Beghi, E., Carpio, A., Forsgren, L., Hesdorffer, D. C., Malmgren, K., Sander, J. W., Tomson, T., & Hauser, W. A. (2009). Recommendation for a definition of acute symptomatic seizure. Epilepsia. https://doi.org/10.1111/j.1528-1167.2009.02285.x
37. Bertodo, T. D. S., Gross, M. S., & Maldaner, E. B. (2018). TRANSTORNOS BIPOLAR E DEPRESSIVO: UMA REVISÃO DOS ASPECTOS CONCEITUAIS.
38. Bindu, P. S., Nagappa, M., Bharath, R. D., & Taly, A. B. (2017). Isolated Sulfite Oxidase Deficiency.
39. Bitnun, A., & Richardson, S. E. (2015). Childhood Encephalitis in Canada in 2015. Canadian Journal of Infectious Diseases and Medical Microbiology. https://doi.org/10.1155/2015/947602
40. Bivoleanu, A., Avasiloaiei, A., Moscalu, M., & Stamatin, M. (2017). The Role of Follow-up in Monitoring the Outcomes of Prematurity in a Cohort of Romanian Infants. Balkan Medical Journal. https://doi.org/10.4274/balkanmedj.2015.1125
41. Bjorvatn, B., Jernelöv, S., & Pallesen, S. (2021). Insomnia – A Heterogenic Disorder Often Comorbid With Psychological and Somatic Disorders and Diseases: A Narrative Review With Focus on Diagnostic and Treatment Challenges. Frontiers in Psychology. https://doi.org/10.3389/fpsyg.2021.639198
42. Blay, S. L. (2011). A Case of Major Depressive Disorder and Symptoms of Polycystic Ovary Syndrome Responding to Escitalopram. The Primary Care Companion For CNS Disorders. https://doi.org/10.4088/pcc.11l01183
43. Blythe, S. G., Beuret, L. J., Blythe, P., & Scaramella-Nowinski, V. (2017). The Significance of Primitive and Postural Reflexes. https://doi.org/10.1002/9781119164746.ch2
44. Bosanac, B., Dominik, P., Gabrić, P., Hrstić, A., Ključarić, D. K., Kužina, I., Sović, M. S., & Vandek, M. (2017). Lexical-semantic categorisation in patients of schizophrenia. https://doi.org/10.5281/zenodo.4681378
45. Bould, H., Lewis, G., Emond, A., & Crawley, E. (2010). Depression and anxiety in children with CFS/ME: cause or effect?. Archives of Disease in Childhood. https://doi.org/10.1136/adc.2009.173161
46. Boyer, S. (2016). Contribution de l'analyse du signal vocal à la détection de l'état de somnolence et du niveau de charge mentale.
47. Bravo, B., González, S. M. B., Portilla, N. O., Laynez, M. E. G., Gutiérrez, N. S., & Sánchez, F. G. (2024). Schizophreniform disorder. Clinical manifestations and diagnosis. Purposely a case. European Psychiatry. https://doi.org/10.1192/j.eurpsy.2024.1542
48. Brock, S., Dobyns, W. B., & Jansen, A. (2014). PAFAH1B1-Related Lissencephaly/Subcortical Band Heterotopia.
49. Bromberger, J. T. (1998). Gender and Depression. https://doi.org/10.1093/oso/9780195113969.003.0003
50. Brown, G. W., & Birley, J. L. T. (1970). Crises and Life Changes preceding the Onset or Relapse of Acute Schizophrenia: Clinical Aspects. The British Journal of Psychiatry. https://doi.org/10.1192/bjp.116.532.327
51. Brunet, A., Weiss, D. S., Metzler, T. J., Best, S. R., Fagan, J., Vedantham, K., & Marmar, C. R. (2000). An overview of the Peritraumatic Distress Scale. Dialogues in Clinical Neuroscience. https://doi.org/10.31887/dcns.2000.2.1/abrunet
52. Brust, J. C. (2001). Music and the Neurologist. Annals of the New York Academy of Sciences. https://doi.org/10.1111/j.1749-6632.2001.tb05730.x
53. Buckley, P., & Foster, A. (2014). Schizophrenia. https://doi.org/10.1007/978-3-7091-0715-7_4
54. Burkart, J., Jong, M. C., Ilenkyo, L., Verwer, C., Weber, S., Keller, T., & Klement, P. (2017). P172 Results of a randomised controlled trial with a homeopathic complex medicinal product in children with sleep disorders and restlessness. https://doi.org/10.1136/archdischild-2017-313273.260
55. Cadoret, R. J., & Winokur, G. (1972). Genetic Principles in the Classification of Affective Illnesses. International Journal of Mental Health. https://doi.org/10.1080/00207411.1972.11448572
56. Calvanio, R., Levine, M., Deng, W., Song, B., Bunda, B., Fisher, L., Lee, R., Goldstein, R., Buonanno, F. S., & Ning, M. (2018). Abstract WP296: Prospective e-Diary Captures Elusive Oost Stroke-Symptoms as Patterned and Cyclical. Stroke. https://doi.org/10.1161/str.49.suppl_1.wp296
57. Campos, J. G., Guevara, L. G. D., Cano, J. U., Tinedo, R., Villamizar, M., & Rojas, L. M. A. (2005). Hemiplejía alternante de la infancia tratada como epilepsia. Dos nuevos casos. Revista de Neurología. https://doi.org/10.33588/rn.4006.2004494
58. Cao, F., Salem, H., Nagpal, C., & Teixeira, A. L. (2017). Prolonged delirium misdiagnosed as a mood disorder. Dementia & Neuropsychologia. https://doi.org/10.1590/1980-57642016dn11-020014
59. Carpenter, W. T., & Kirkpatrick, B. (1988). The Heterogeneity of the Long-Term Course of Schizophrenia. Schizophrenia Bulletin. https://doi.org/10.1093/schbul/14.4.645
60. Carvajal, C. (2004). Poor response to treatment: beyond medication. Dialogues in Clinical Neuroscience. https://doi.org/10.31887/dcns.2004.6.1/ccarvajal
61. Carvajal, C. (2004). Poor response to treatment: beyond medication.. PubMed.
62. Carvajal-Lohr, A., Flores‐Ramos, M., Montejo, S. I., & Vidal, C. G. (2016). Los trastornos de ansiedad durante la transición a la menopausia. Perinatología y Reproducción Humana. https://doi.org/10.1016/j.rprh.2016.03.003
63. Casey, P. (2018). Making the diagnosis in clinical practice (DRAFT). Oxford University Press eBooks. https://doi.org/10.1093/med/9780198786214.003.0006
64. Castro, N., & Paola, L. (2018). Programa educativo para disminuir el trastorno depresivo en el post parto en madres primerizas atendidas en el servicio de gineco-obstetricia del hospital general Ambato.
65. Ceravolo, F., Sestito, S., Falvo, F., Salpietro, V., Polizzi, A., Ruggieri, M., Bruno, M., & Concolino, D. (2016). Neurological Involvement in Inherited Metabolic Diseases: An Overview. Journal of Pediatric Biochemistry. https://doi.org/10.1055/s-0036-1582235
66. Chaijan, P. Y., Salehi, B., Khosrobeigi, A., Hajirahimi, M., Rafiei, M., & Ahmadi, H. T. (2014). Prevalence of Obsessive-Compulsive Disorder in Pediatric Patients with the Daytime Frequency Syndrome of Childhood or Pollakiuria. Journal of Arak University of Medical Sciences.
67. Challacombe, F., & Wroe, A. L. (2013). A hidden problem: consequences of the misdiagnosis of perinatal obsessive–compulsive disorder. British Journal of General Practice. https://doi.org/10.3399/bjgp13x667376
68. Charmandari, E., Kino, T., Souvatzoglou, E., & Chrousos, G. P. (2003). Pediatric Stress: Hormonal Mediators and Human Development. Hormone Research in Paediatrics. https://doi.org/10.1159/000069325
69. Chen, D., & LaFrance, W. C. (2018). Epilepsy and Seizures. American Psychiatric Association Publishing eBooks. https://doi.org/10.1176/appi.books.9781615372423.sy10
70. Chua, A. S. B. (2011). Prevalence of Irritable Bowel Syndrome in Northern India. Journal of Neurogastroenterology and Motility. https://doi.org/10.5056/jnm.2011.17.1.6
71. Cisneros, V., & Wray, A. (2017). Febrile Seizure. Journal of Education and Teaching in Emergency Medicine. https://doi.org/10.5070/m521033761
72. Clunie, G., Wilkinson, N., Nikiphorou, E., & Jadon, D. R. (2018). Evaluating rheumatological and musculoskeletal symptoms. Oxford University Press eBooks. https://doi.org/10.1093/med/9780198728252.003.0001
73. Coghill, D., Bonnar, S., Duke, S. E., Graham, J., & Seth, S. G. (2009). Pre-school problems. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199234998.003.0006
74. Coghill, D., Bonnar, S., Duke, S., Graham, J., & Seth, S. (2009). Obsessive compulsive disorder. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199234998.003.0020
75. Coghill, D., Bonnar, S., Duke, S., Graham, J., & Seth, S. (2009). The pervasive developmental disorders. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199234998.003.0010
76. Cole, J., & Katz, M. M. (1964). THE PSYCHOTOMIMETIC DRUGS. AN OVERVIEW.. PubMed.
77. Cole, J., & Katz, M. M. (1964). The Psychotomimetic Drugs. JAMA. https://doi.org/10.1001/jama.1964.03060230086021
78. Colán, T. C., Gálvez, G. A., & Zevallos, D. C. (2013). Síntomas psiquiátricos e insulinoma: reporte de caso Psychiatric symptoms and insulinoma: a case report.
79. Cooper, L., Copeland, S., Dailey, S., Downey, D., Petersen, M. C., Stimson, C., & Dyke, D. C. V. (2008). Feeding and swallowing dysfunction in genetic syndromes. Developmental Disabilities Research Reviews. https://doi.org/10.1002/ddrr.19
80. Coronado, L. M. Q., Florez, D. A. C., & Tarazona, M. C. L. (2017). Prevalencia depresión en estudiantes universitarios Bucaramanga 2017.
81. Couto, F. S. D., & Mendonça, A. D. (2010). Sintomas psiquiátricos e comportamentais da demência. Revista Portuguesa de Clínica Geral. https://doi.org/10.32385/rpmgf.v26i1.10713
82. Cunningham, J., Yonkers, K. A., O’Brien, S., & Eriksson, E. (2009). Update on Research and Treatment of Premenstrual Dysphoric Disorder. Harvard Review of Psychiatry. https://doi.org/10.1080/10673220902891836
83. Dahlem, M. A., Mair, T., & Müller, S. C. (2004). Spatio-Temporal Aspects of a Dynamical Disease: Waves of Spreading Depression. Birkhäuser Basel eBooks. https://doi.org/10.1007/978-3-0348-7895-1_42
84. Debiais, S., Bonnaud, I., Ferreira-Maldent, N., Mercier, E., & Toffol, B. D. (2009). NEUROPSYCHIATRIC DISORDERS REVEALING PRIMARY ANTIPHOSPHOLIPID SYNDROME IN AN ELDERLY PATIENT. Neurology. https://doi.org/10.1212/wnl.0b013e3181a0fd69
85. Demey, I., Zimerman, M., Allegri, R., Serrano, C., & Taragano, F. (2004). Neuropsychiatric symptoms of mild cognitive impairment. CRC Press eBooks. https://doi.org/10.3109/9780203492857-7
86. Deonna, T., Roulet, E., Gaillard, F., Peter-Favre, C., & Despland, P. (1991). Acquired Aphasia, Dementia, and Behavior Disorder with Epilepsy and Continuous Spike and Waves During Sleep in a Child. Epilepsia. https://doi.org/10.1111/j.1528-1157.1991.tb04683.x
87. Derkach, T., Lifintseva, A. A., & Shtolde, N. (2018). Phenomenon of Uncertainty as a Subjective Experience. Clinical Psychology and Special Education. https://doi.org/10.17759/cpse.2018070101
88. Dhobe, S., Gujar, S., & Sc, M. (2021). Prevalence of Associated Factors of Depressive Symptoms among School Going Children’s. Indian Journal of Forensic Medicine & Toxicology. https://doi.org/10.37506/ijfmt.v15i1.13470
89. Dodd, M. L. (2007). BASIC PRINCIPLES OF PSYCHIATRY. CRC Press eBooks. https://doi.org/10.1201/b14430-11
90. Dodick, D. W., & Roarke, M. C. (2007). Familial Hemiplegic Migraine: Permanent Attack‐Related Neurologic Deficits. Headache The Journal of Head and Face Pain. https://doi.org/10.1111/j.1526-4610.2007.00889.x
91. Dragut, A. M., Danalache, I., Goanta, M., & Trifu, S. (2015). The Pathology of Cognitive and Language Disorganization–Between Hysteric Dissociation and Schizophrenic Split. Procedia - Social and Behavioral Sciences. https://doi.org/10.1016/j.sbspro.2015.03.081
92. Duval, F., Jautz-Duval, M. M., González, F., & Rabia, H. (2010). Bases neurobiológicas de vulnerabilidad psiquiátrica a lo largo de las etapas de la vida hormonal de la mujer. Revista chilena de neuro-psiquiatría. https://doi.org/10.4067/s0717-92272010000500005
93. Dılbaz, N., & Enez, A. (2013). Treatment of Generalized Anxiety Disorders: Unmet Needs. InTech eBooks. https://doi.org/10.5772/53453
94. Emilien, G., Durlach, C., Minaker, K. L., Winblad, B., Gauthier, S., & Maloteaux, J. (2004). Behavioral and psychological impairments. Birkhäuser Basel eBooks. https://doi.org/10.1007/978-3-0348-7842-5_9
95. Ensalada, L. (2011). Behavioral Factors Impact Impairment and Disability Evaluation. AMA guides newsletter. https://doi.org/10.1001/amaguidesnewsletters.2011.sepoct03
96. Escribano, S. A. (2018). Estudio de la eficacia de un tratamiento psicológico breve en la disminución de la sensibilidad a la ansiedad en pacientes con trastorno de pánico.
97. Eskander, F. S. L., Hakim, K. Y. K., Ibrahim, D., & ElMallah, W. (2021). Incidence Of Post-Operative Delirium In Geriatric Patients Undergoing Hip Replacement Surgery Using Pre-Operative Haloperidol. QJM. https://doi.org/10.1093/qjmed/hcab086.109
98. Fenton, W. S. (1991). Natural History of Schizophrenia Subtypes. Archives of General Psychiatry. https://doi.org/10.1001/archpsyc.1991.01810350018003
99. Filipa, N., & Sergio, S. (2015). Phenomenology of Depression in Alzheimer's Disease. Advances in Alzheimer's disease. https://doi.org/10.3233/978-1-61499-542-5-3
100. Fink, M. (2010). Movement Disorders. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780195365740.003.0011
101. Fitzgerald, C., & Patten, S. B. (2008). Is Multiple Sclerosis Patient Depressed, Stressed, or Both? How to Sort through Overlapping Symptoms and Provide Appropriate Treatment. Current psychiatry.
102. Fletcher, P. C. (2003). Functional neuroimaging of schizophrenia: from a genetic predisposition to the emergence of symptoms. Brain. https://doi.org/10.1093/brain/awh113
103. Forbes, F. (2010). Improving recognition and management of ADHD.. Practitioner.
104. Fowler, D. (2024). The promise of social recovery therapy in non‐affective psychoses. World Psychiatry. https://doi.org/10.1002/wps.21208
105. Franjić, S. (2021). Deaf Patient – Empediment or Not. https://doi.org/10.47310/iarjcr.2021.v01i01.002
106. Gaby, A. R. (2009). Integrative Approaches to Ménière's Disease.
107. Gautam, S., Jain, A., Gautam, M., Vahia, V., & Gautam, A. (2017). Clinical Practice Guidelines for the Management of Generalised Anxiety Disorder (GAD) and Panic Disorder (PD). Indian Journal of Psychiatry. https://doi.org/10.4103/0019-5545.196975
108. Gavazzi, F., Charsar, B. A., Williams, C., Shults, J., Alves, C. A. P. F., Adang, L., & Vanderver, A. (2021). Acquisition of Developmental Milestones in Hypomyelination With Atrophy of the Basal Ganglia and Cerebellum and Other TUBB4A-Related Leukoencephalopathy. Journal of Child Neurology. https://doi.org/10.1177/08830738211000977
109. Geller, E., Ritvo, E., Freeman, B. J., & Yuwiler, A. (1982). Preliminary Observations on the Effect of Fenfluramine on Blood Serotonin and Symptoms in Three Autistic Boys. New England Journal of Medicine. https://doi.org/10.1056/nejm198207153070307
110. Gentile, J. P. (2018). Aggression in Intellectual Disability. International Journal of Autism & Related Disabilities. https://doi.org/10.29011/2642-3227.000010
111. Gibson, R. H. (1952). DIFFERENTIAL DIAGNOSIS OF OLIGOPHRENIA. Archives of Pediatrics and Adolescent Medicine. https://doi.org/10.1001/archpedi.1952.02040060017001
112. Gilbert‐Barness, E., Debich-Spicer, D., & Opitz, J. M. (2001). Malformation Syndromes. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511547423.010
113. Globas, C., Montcel, S. T. D., Baliko, L., Boesch, S., Depondt, C., DiDonato, S., Dürr, A., Filla, A., Klockgether, T., Mariotti, C., Melegh, B., Rakowicz, M., Ribaı̈, P., Rola, R., Schmitz‐Hübsch, T., Szymanski, S., Timmann, D., Warrenburg, B. P. V. D., Bauer, P., & Schöls, L. (2008). Early symptoms in spinocerebellar ataxia type 1, 2, 3, and 6. Movement Disorders. https://doi.org/10.1002/mds.22288
114. Golden, C. J., & Golden, Z. L. (2004). Traumatic Brain Injury. Routledge eBooks. https://doi.org/10.4324/9780203336960-19
115. Goodyer, I., Herbert, J., Tamplin, A. K., & Altham, P. M. E. (2000). Recent life events, cortisol, dehydroepiandrosterone and the onset of major depression in high-risk adolescents. The British Journal of Psychiatry. https://doi.org/10.1192/bjp.177.6.499
116. Grande, J. P. (2018). Semiología onírica del sonambulismo: implicaciones patogénicas y clínicas.
117. Gregory, A., Kurian, M. A., Haack, T. B., Hayflick, S. J., & Hogarth, P. (2017). Beta-Propeller Protein-Associated Neurodegeneration.
118. Gregory, A., Kurian, M. A., Maher, E. R., Hogarth, P., & Hayflick, S. J. (2015). PLA2G6-Associated Neurodegeneration.
119. Grigorenko, E. L., Klin, A., & Volkmar, F. R. (2003). Annotation: Hyperlexia: disability or superability?. Journal of Child Psychology and Psychiatry. https://doi.org/10.1111/1469-7610.00193
120. Groisman, A. E., & Seminatore, M. L. (2003). Children and Adolescents Who Have Schizophrenia. Pediatrics in Review. https://doi.org/10.1542/pir.24.10.356
121. Gutiérrez-Achury, A. M., Vanegas-Vidal, M., Salazar-Díaz, L. I., & Arías, G. M. A. (2009). Factores farmacológicos y no farmacológicos que afectan la adherencia al tratamiento de los pacientes esquizofrénicos dados de alta en la Unidad de Salud Mental del Hospital Universitario de Neiva entre enero y junio del 2008. RFS Revista Facultad de Salud. https://doi.org/10.25054/rfs.v1i2.43
122. Guédeney, A., & Kreisler, L. (1987). Sleep disorders in the first 18 months of life: Hypothesis on the role of mother-child emotional exchanges. Infant Mental Health Journal. https://doi.org/10.1002/1097-0355(198723)8:3<307::aid-imhj2280080312>3.0.co;2-v
123. Gómez‐Revuelta, M., Blanco, L. S., Ruíz, M. J., Jenaro, G. P. D. S., Rodríguez, R. L., Olivares, O. P., & Morales, N. N. (2017). A Clinical review about differential diagnosis and comorbidities on premenstrual dysphoric disorder. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2017.01.577
124. Harvey, P. D. (2010). Schizophrenia, Functional Outcomes in. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy0822
125. Hawkes, M. A., & Hocker, S. E. (2021). Status Epilepticus. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197512166.003.0057
126. Hills, H. A., Siegfried, C., & Ickowitz, A. (2004). Effective prison mental health services: Guidelines to expand and improve treatment. PsycEXTRA Dataset. https://doi.org/10.1037/e306322005-001
127. Hirschfeld, R. M. A., Calabrese, J. R., Frye, M. A., Lavori, P. W., Sachs, G., Thase, M. E., & Wagner, K. D. (2007). Defining the clinical course of bipolar disorder: response, remission, relapse, recurrence, and roughening.. PubMed.
128. Hocker, S. E., Wijdicks, E. F. M., & Rabinstein, A. A. (2013). Refractory status epilepticus: new insights in presentation, treatment, and outcome. Neurological Research. https://doi.org/10.1179/1743132812y.0000000128
129. Hudson, A., Taylor, D., Lee, K. A., & Gilliss, C. L. (2005). Symptom experience and self-care strategies among healthy, midlife African-American women.. PubMed.
130. Iqbal, M., Yarahmadi, A., Ashraf, F., & Rosen, C. (2017). 1255 An Unusual Clinical Presentation of a Parasomnia. SLEEP. https://doi.org/10.1093/sleepj/zsx052.045
131. Ishikawa, T., Nakazato, M., Awaya, A., & Kanayarna, M. (1988). Benign Childhood Epilepsy with Centro‐Temporal Spikes: Evolution of Seizure Types. Pediatrics International. https://doi.org/10.1111/j.1442-200x.1988.tb02500.x
132. Isometsä, E., Kinnunen, E., Kivekäs, T., Koponen, H., Lappalainen, J., Lindfors, O., Marttunen, M., Pirkola, S., Jousilahti, P., & Tuunainen, A. (2015). [Update on Current Care Guideline: Depression].. PubMed.
133. Issa, B. A. (2013). Prevalence and Correlates of Depressive Disorders among People Living with HIV/AIDS, in North Central Nigeria. Journal of AIDS & Clinical Research. https://doi.org/10.4172/2155-6113.1000251
134. Ivarsson, S. A., Johansson, O., Neiderud, J., & Lindberg, T. (1988). CHARGE‐Association with Pulmonary Stenosis. Acta Paediatrica. https://doi.org/10.1111/j.1651-2227.1988.tb10782.x
135. İbiloğlu, A. O., Atlı, A., Kaya, M. C., Baran, A. S., & Sır, A. (2016). Psychogenic Gait Disorder After a Stressful Life Event: Case Report. Turkiye Klinikleri Journal of Case Reports. https://doi.org/10.5336/caserep.2015-46732
136. Jain, S., Goel, S., & Kapila, S. (2015). Clinical Evaluation Of Psychiatric Emergencies.
137. Jan, M. M., Banji, M. H. A., & Fallatah, B. A. (2013). Long-term Outcome of Infantile Gratification Phenomena. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques. https://doi.org/10.1017/s0317167100014396
138. Judge, A. C. D. E. (2004). SSRIs: Effective Treatment for Depression. Journal watch. https://doi.org/10.1056/wh200411030000009
139. Kanchanatawan, B., & Kasantikul, D. (2007). Antipsychotic-induced tardive movement disorders: a series of twelve cases.. PubMed.
140. Kataoka, K., Nakagawa, Y., & Hojo, H. (1984). Intractable Seizures in Infancy and Early Childhood Excluding West and Lennox-Gastaut Syndrome. Journal of the Japan Epilepsy Society. https://doi.org/10.3805/jjes.2.13
141. Kelly, F. D. (2010). Adjustment Disorder. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy0015
142. Kelly, S. D. (2021). The Acute Stress Syndrome Stabilization Remote Individual (ASSYST-RI) for TeleMental Health Counseling After Adverse Experiences. Psychology and Behavioral Science International Journal. https://doi.org/10.19080/pbsij.2021.16.555932
143. Kennedy, S. H. (2008). Core symptoms of major depressive disorder: relevance to diagnosis and treatment. Dialogues in Clinical Neuroscience. https://doi.org/10.31887/dcns.2008.10.3/shkennedy
144. Kessler, R. C., & Wang, P. S. (2008). The Descriptive Epidemiology of Commonly Occurring Mental Disorders in the United States. Annual Review of Public Health. https://doi.org/10.1146/annurev.publhealth.29.020907.090847
145. Khaikin, Y., & Mercimek‐Andrews, S. (2016). STXBP1 Encephalopathy with Epilepsy.
146. Khan, A. Y., Kalia, R., Ide, G. D., & Ghavami, M. (2017). What Are Realistic Treatment Goals? Lingering Symptoms Require You to Evaluate Pharmacotherapy and Offer Psychosocial Interventions. Current psychiatry.
147. Kim, S.-H. (2015). Neurogenic Bladder Dysfunction Caused by Seronegative Autoimmune Autonomic Ganglionopathy. Soonchunhyang Medical Science. https://doi.org/10.15746/sms.15.010
148. Klassen-Bolding, S., & Lenz, A. S. (2016). Post-traumatic Stress Disorder in Youth. https://doi.org/10.63134/mwtw7144
149. Klawans, H. L., Tanner, C. R. M., & Barr, A. (1984). The Reversibility of “Permanent” Tardive Dyskinesia. Clinical Neuropharmacology. https://doi.org/10.1097/00002826-198406000-00006
150. Klein, S. (2015). Autistic phenomena in neurotic patients 1. Routledge eBooks. https://doi.org/10.4324/9781315743882-10
151. Klipstein, A., & Nydegger, A. (2013). Rückenschmerzen im Erwerbstätigenalter. Therapeutische Umschau. https://doi.org/10.1024/0040-5930/a000440
152. Knaap, M. S. V. D., Depienne, C., Sedel, F., & Abbink, T. E. M. (2015). CLCN2-Related Leukoencephalopathy.
153. Kotade, K. B., Pandit, B. S., Gaware, V. M., Dolas, R. T., Dhamak, K. B., Somwanshi, S. B., Nikam, V. K., & Khadse, A. N. (2011). KNOWING DEPRESSION AND PHARMACOLOGICAL, NON-PHARMACOLOGICAL APPROACHES FOR ITS TREATMENT.
154. Kučikienė, O., Lesauskaitė, V., Macijauskienė, J., Vainoras, A., Blaževičienė, A., Samėnienė, J., Alekna, V., Satkunskienė, D., Naudžiūnas, A., & Krutulytė, G. (2009). Dažniausi hospitalizuotų pagyvenusio amžiaus pacientų sveikatos sutrikimai.
155. Kverno, K., Rabins, P. V., Blass, D., Hicks, K. L., & Black, B. S. (2008). Prevalence and Treatment of Neuropsychiatric Symptoms in Hospice-Eligible Nursing Home Residents with Advanced Dementia. Journal of Gerontological Nursing.
156. Lam, R. W. (2018). Associated clinical features. Depression. https://doi.org/10.1093/med/9780198804147.003.0005
157. Landolfi, M., Parise, V. F., Balletta, G., & Manna, G. L. (2011). Recovery Versus Remission in Schizophrenia and Related Persistent Psychotic Disorders: no Contrasting but Complementary Models. European Psychiatry. https://doi.org/10.1016/s0924-9338(11)73091-7
158. Lansky, M. R. (1989). The Explanation of Impulsive Action. British Journal of Psychotherapy. https://doi.org/10.1111/j.1752-0118.1989.tb01259.x
159. Latronico, N., Antonini, L., Taricco, M., Vignolo, L., & Candiani, A. (2000). [Approach to the patient in vegetative state. Part II: differential diagnosis].. PubMed.
160. Latta, F., & Cauter, E. V. (2003). Sleep and Biological Clocks. Handbook of Psychology. https://doi.org/10.1002/0471264385.wei0313
161. Lee, E., Cheuk, J. T. Y., & Ungvári, G. S. (2009). A Patient with Chronic Schizophrenia Presenting with Multiple Deliberate Self-Harm and Genital Self-Mutilation. Hong Kong journal of psychiatry.
162. Leoni, M. C., Pizzo, D., Rundo, B., Tasso, G., & Marchi, A. (2009). Atassia in ex-prematuro: un caso pediatrico. Bollettino della Società Medico Chirurgica di Pavia. https://doi.org/10.6092/2039-1404.122.404
163. Lewandowska, A., & Rybakowski, J. (2009). [Neuropsychological aspects of the manic syndrome in the course of bipolar affective illness].. PubMed.
164. Lewis, S., Tarrier, N., & Drake, R. (2005). Integrating non-drug treatments in early schizophrenia. The British Journal of Psychiatry. https://doi.org/10.1192/bjp.187.48.s65
165. León, M. S. M. D. (2017). Trastorno por déficit de atención con hiperactividad: autorregulación emocional y funciones ejecutivas.
166. León, S. O., & Medrano, A. L. J. (2016). Trastorno por déficit de atención en la edad adulta y en universitarios. Revista de la Facultad de Medicina (México).
167. Lečić-Toševski, D. M., Pejović-Milovančević, M., Popović-Deušić, S., & Šušić (2007). [Psychiatric aspects of sleep].. PubMed.
168. Liberalesso, P. B. N. (2018). Epileptic Syndromes in Childhood. A Practical Approach. Residência Pediátrica. https://doi.org/10.25060/residpediatr-2018.v8s1-10
169. Lichter‐Konecki, U., Caldovic, L., Morizono, H., & Simpson, K. (2011). Ornithine transcarbamylase deficiency. CRC Press eBooks. https://doi.org/10.1201/b13564-28
170. Liddle, P. F. (1987). The Symptoms of Chronic Schizophrenia. The British Journal of Psychiatry. https://doi.org/10.1192/bjp.151.2.145
171. Lievre, J. A. L., Schweitzer, R., & Barnard, A. (2011). The subjective experience of negative symptoms : characteristics of emotional withdrawal. Routledge eBooks.
172. Linzer, S., Chesir, A., Ginsburg, T., & Varas, O. (2017). Stressful Life Events. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190260859.003.0005
173. Lockhart, P. J. (2001). Fetal alcohol spectrum disorders for mental health professionals - a brief review. Current Opinion in Psychiatry. https://doi.org/10.1097/00001504-200109000-00007
174. Loranger, A. W. (1984). Schizophrenia and Age Considerations-Reply. Archives of General Psychiatry. https://doi.org/10.1001/archpsyc.1984.01790190093015
175. Luijendijk, H. J. (2010). Vascular Heart and Brain Disease and Incident Late-Life Depression.
176. Ma, J., & Junqué, C. (2001). [Criminal behavior after orbitofrontal lesion].. PubMed.
177. MacDonald, J. T. (1988). Childhood seizures. Postgraduate Medicine. https://doi.org/10.1080/00325481.1988.11700221
178. Macneil, C., Hasty, M., Conus, P., Berk, M., & Scott, J. (2009). Social rhythm regulation. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511757389.008
179. Madruga, M. L. L. H., Melo, G. B., Martins, J. M., Aranha, R. E. L. D. B., Marinho, J. C. R. L., Alves, N. T., Estudo, E., Revisão, U., & Literatura, D. (2018). Estudo Eletroencefalográfico De Indivíduos Com Dor Crônica Decorrente Da Fibromialgia: Uma Revisão Da Literatura. Scientific Research and Reviews. https://doi.org/10.28933/srr-2018-06-28100
180. Mahon, S. M., & Carr, E. (2021). Fatigue/Lack of Endurance: Common Side Effect. Clinical journal of oncology nursing. https://doi.org/10.1188/21.cjon.s2.25
181. Malaty, J., & Malaty, I. A. (2013). Smell and taste disorders in primary care.. PubMed.
182. Malenfant, M., Tremblay, S., Laurin, D., & Lefèbvre, J. (2008). L'utilisation du citalopram pour traiter l'agitation et les symptômes psychotiques chez les patients souffrant de démence.
183. Mameniškienė, R., Bast, T., Bentes, C., Canevini, M. P., Dimova, P., Granata, T., Høgenhaven, H., Jakubi, B. J., Marusič, P., Melikyan, G., Michelucci, R., Мukhin, К. Y., Oehl, B., Ragona, F., Rossetti, A. O., Rubboli, G., Schubert‐Bast, S., Stephani, U., Strobel, J., ... Wolf, P. (2011). Clinical course and variability of non-Rasmussen, nonstroke motor and sensory epilepsia partialis continua: A European survey and analysis of 65 cases. Epilepsia. https://doi.org/10.1111/j.1528-1167.2010.02974.x
184. Mamidi, P., & Gupta, K. (2018). Brahma rakshasa grahonmada: Borderline personality disorder?/tourette syndrome – plus?. International Journal of Yoga - Philosophy Psychology and Parapsychology. https://doi.org/10.4103/ijny.ijoyppp_14_17
185. Maramis, M. M. (2009). Mengenal Gangguan Mood pada Perempuan.
186. Martel, M. M. (2009). Research Review: A new perspective on attention‐deficit/hyperactivity disorder: emotion dysregulation and trait models. Journal of Child Psychology and Psychiatry. https://doi.org/10.1111/j.1469-7610.2009.02105.x
187. Martı́n, M. Á., Remschmidt, H., Schulz, E., Warnke, A., & Trott, G.-E. (1994). Childhood-Onset Schizophrenia: History of the Concept and Recent Studies. Schizophrenia Bulletin. https://doi.org/10.1093/schbul/20.4.727
188. María, A., Sancho, R., & Pita, B. L. (2005). Trastornos de ansiedad en la infancia y en la adolescencia.
189. Marín, H., Menza, M., & Dobkin, R. D. (2007). Parkinson's Symptoms or Depression? Look for Clinical Signs: How to Sort through Overlapping Symptoms Using DSM-IV-TR Diagnostic Criteria. Current psychiatry.
190. Masgutova, S., Wenberg, S., & Retschler, M. (2008). MASGUTOVA METHOD OF REFLEX INTEGRATION FOR CHILDREN WITH CEREBRAL PALSY.
191. Mazzoni, P., Kimhy, D., Khan, S., Posner, K., Maayan, L., Eilenberg, M., Walsh‐Messinger, J., Kestenbaum, C. J., & Corcoran, C. M. (2009). Childhood Onset Diagnoses in a Case Series of Teens at Clinical High Risk for Psychosis. Journal of Child and Adolescent Psychopharmacology. https://doi.org/10.1089/cap.2008.0105
192. McFarlane, S. I. (2021). Editorial Note on Psychosis. Brain Disorders & Therapy. https://doi.org/10.35248/2168-975x.21.s2.e003
193. McGlashan, T. H. (1992). The Positive-Negative Distinction in Schizophrenia. Archives of General Psychiatry. https://doi.org/10.1001/archpsyc.1992.01820010063008
194. Medina-Chávez, J. H., Fuentes-Alexandro, S., Gil-Palafox, I. B., Adame-Galván, L., Solís-Lam, F., Sánchez-Herrera, L. Y., & Narváez, F. S. (2014). [Clinical practice guideline. Diagnosis and treatment of insomnia in the elderly].. PubMed.
195. Medina-Chávez, J. H., Fuentes-Alexandro, S., Gil-Palafox, I. B., Adame-Galván, L., Solís-Lam, F., Sánchez-Herrera, L. Y., & Narváez, F. S. (2014). Diagnóstico y tratamiento del insomnio en el adulto mayor.
196. Medrano‐Martínez, P., Platón, M., & Peraita‐Adrados, R. (2018). Alteraciones neuropsicológicas en la narcolepsia con cataplejía: una revisión. Revista de Neurología. https://doi.org/10.33588/rn.6603.2017448
197. Meehl, P. E. (1989). Schizotaxia Revisited. Archives of General Psychiatry. https://doi.org/10.1001/archpsyc.1989.01810100077015
198. Mellero, D. (2007). Ansiedade em situações de convívio social em idosos.
199. Menéndez, S. F., González, J. M. G., Antuña, V. Á., & Bobes, J. (2016). La demencia del rey Fernando VI y el año sin rey. Revista de Neurología. https://doi.org/10.33588/rn.6211.2016040
200. Mervis, C. Β., Morris, C. A., Klein-Tasman, B., Velleman, S. L., & Osborne, L. R. (2015). 7q11.23 Duplication Syndrome.
201. Mian, N. D., & Carter, A. S. (2013). Recognition and Assessment of Anxiety & Depression in Early Childhood.
202. Miller, R. L., & Mason, S. E. (2011). What Is Schizophrenia?. Columbia University Press eBooks. https://doi.org/10.7312/columbia/9780231150415.003.0004
203. Miller, S. P., & Latal, B. (2009). Neurocognitive outcomes of term infants with perinatal asphyxia. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511581281.050
204. Mircher, C., Cieuta‐Walti, C., Marey, I., Rebillat, A., Cretu, L., Milenko, E., Conte, M., Sturtz, F., Rethoré, M. O., & Ravel, A. (2017). Acute Regression in Young People with Down Syndrome. Brain Sciences. https://doi.org/10.3390/brainsci7060057
205. Montalto, S. A. (2021). Intrapartum Asphyxia and Its Sequelae. Cambridge University Press eBooks. https://doi.org/10.1017/9781108863049.061
206. Montes, A. B., & Rey, J. A. (2009). Iloperidone (Fanapt): An FDA-Approved Treatment Option for Schizophrenia. P & T.
207. Mori, T., & Kumai, M. (2009). Development of Auditory Function, Language and Characteristic Behaviors in a Hearing-Impaired Infant Suspected with Attention Deficit/Hyperactivity Disorder. The Japan Journal of Logopedics and Phoniatrics. https://doi.org/10.5112/jjlp.50.173
208. Moster, R. L., Siever, L. J., & Frangou, S. (2016). Schizophrenia Spectrum and Other Psychotic Disorders. https://doi.org/10.1002/9781118654231.ch15
209. Motoki, T., Sasaki, M., Ishii, A., & Hirose, S. (2016). [Characteristic asymmetric abnormal eye movement and dystonic posture as the first symptoms of alternating hemiplegia of childhood].. PubMed.
210. Moura, G. S., Neves, L. M. T., Giorelli, A. S., Florido, P., & Gomes, M. D. M. (2013). Transtornos do sono: visão geral Sleep disorders: overview.
211. Mucci, A., & Galderisi, S. (2017). The Evolution of Negative Symptom Constructs. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2017.01.096
212. Mucci, A., Bucci, P., Giordano, G. M., Brando, F., & Galderisi, S. (2021). Apathy in schizophrenia: assessment in clinical settings and overlap with other dimensions of impairment. European Psychiatry. https://doi.org/10.1192/j.eurpsy.2021.159
213. Mucha, B. E., Hennekam, R. C. M., Sisodiya, S. M., & Campeau, P. M. (2015). TBC1D24-Related Disorders.
214. Mullen, S. (2018). Major depressive disorder in children and adolescents. Mental Health Clinician. https://doi.org/10.9740/mhc.2018.11.275
215. Munir, S., & Takov, V. (2021). Generalized Anxiety Disorder. StatPearls.
216. Munir, S., Takov, V., & Coletti, V. A. (2021). Generalized Anxiety Disorder (Nursing).
217. Møller, J. T. (1998). Postoperative cognitive decline: the extent of the problem. European Journal of Anaesthesiology. https://doi.org/10.1097/00003643-199811000-00027
218. Nakano, A., Nakajima, K., Kobayashi, T., Tsukahara, Y., & Sato, M. (1982). Aphasia-like disorders following left thalamic hemorrhage. Shitsugoshō kenkyū/Shitsugoshou kenkyuu. https://doi.org/10.2496/apr.2.351
219. Narayan, S. K., Sivaprasad, P., Sahoo, R. N., & Bhuvaneswari, V. (2008). Teaching Video Neuro <i>Image</i> : Chvostek sign with Fahr syndrome in a patient with hypoparathyroidism. Neurology. https://doi.org/10.1212/01.wnl.0000336974.93499.ad
220. Nasrallah, H. A. (2009). Diagnosis 2.0 Are Mental Illnesses Diseases, Disorders, or Syndromes? A Major Challenge for the DSM-V Committees as They Revise the Diagnostic "Bible" of Psychiatric Disorders Is to Determine Whether Mental Illnesses Are Diseases, Disorders, or Syndromes. Current psychiatry.
221. Navarra, C. H., Losada, L. L., & Piqueras, J. P. (1988). Ingreso psiquiátrico muy breve. Características en el Hospital Psiquiátrico de Bétera .. Revista de la Asociación Española de Neuropsiquiatría..
222. Nelson, B., & Sass, L. A. (2018). 28.1 VARIETIES OF SELF DISORDER: A BIO-PHENO-SOCIAL MODEL OF SCHIZOPHRENIA. Schizophrenia Bulletin. https://doi.org/10.1093/schbul/sby014.116
223. Niggemann, B. (2011). Introductory lecture: Diagnosis of food allergy: when is an oral challenge positive. Clinical and Translational Allergy. https://doi.org/10.1186/2045-7022-1-s1-s43
224. Nizamie, A., Sengupta, U., Mishra, B. R., Praharaj, S. K., & Nizamie, S. H. (2010). Alka Nizamie;Uma Sengupta;Biswa Ranjan Mishra;Samir Kumar Praharaj;S. Haque Nizamie. Acta Neurologica Taiwanica. https://doi.org/10.29819/ant.201003.0008
225. Nizamie, A., Sengupta, U., Mishra, B. R., Praharaj, S. K., & Nizamie, S. H. (2010). Role of early multimodal interventions in a case with autistic regression.. PubMed.
226. Novak, M. A., & Meyer, J. S. (2021). Abnormal Behavior of Animals in Research Settings. CRC Press eBooks. https://doi.org/10.1201/9780429019517-4
227. Oberklaid, F., & Wright, M. (2003). Child development - issues in early detection. https://doi.org/10.4225/50/5552e6da4fc08
228. Ogawa, T. (2012). [Psychoanalytic study of social withdrawal: grandiose narcissism and passive aggression due to insufficient maternal containing in childhood].. PubMed.
229. Pallesen, S., Olsen, O. K., Eide, E. M., Nortvedt, B., Grønli, J., Larøi, F., Nordmo, M., & Glomlien, F. E. (2018). Sleep deprivation and hallucinations. A qualitative study of military personnel. Military Psychology. https://doi.org/10.1080/08995605.2018.1478561
230. Pandit, M. S., Gupta, A., Mathur, P., Sharma, M., & Garg, M. (2016). JOURNAL OF PEDIATRIC CRITICAL CARE. JOURNAL OF PEDIATRIC CRITICAL CARE. https://doi.org/10.21304/2016.0302.00123
231. Panfilova, E., Bobylova, M. Y., Kapustina, A. A., Braudo, T. A., Abramov, M. O., & Klepikov, N. I. (2017). Motor and sensory alalia: diagnostic difficulties. Russian Journal of Child Neurology. https://doi.org/10.17650/2073-8803-2017-12-4-32-42
232. Park, J. S., Belfort, M. A., & Norwitz, E. R. (2001). Pathogenesis and treatment of eclampsia. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511545634.030
233. Patil, S. R. (2018). TAILA DHARA IN NIDRANASHA W.S.R. TO INSOMNIA. National Journal of Research in Ayurved Science. https://doi.org/10.52482/ayurlog.v6i06.204
234. Patimah, S. (2021). Aplikasi Terapi Bercakap - Cakap Pada Tn. N dengan Gangguan Persepsi Sensori: Halusinasi Pendengaran di Jampang Kulon. Lentera Jurnal Ilmiah Kesehatan dan Keperawatan. https://doi.org/10.37150/jl.v4i1.1382
235. Pavone, P., Corsello, G., Ruggieri, M., Marino, S., Marino, S. D., & Falsaperla, R. (2018). Benign and severe early-life seizures: a round in the first year of life. The Italian Journal of Pediatrics/Italian journal of pediatrics. https://doi.org/10.1186/s13052-018-0491-z
236. Pegrum, S. N. (2009). Putting the pieces together: The subjective experience of anorexia nervosa over the course of the disorder. https://doi.org/10.4226/66/5a95ee1bc6804
237. Pelc, K., Chéron, G., & Dan, B. (2011). The Lessons from Angelman Syndrome for Research and Management. InTech eBooks. https://doi.org/10.5772/21808
238. Pereira, J. A. (2021). Teenager with paranoia and hallucinations preceded by a decline in academic and social functioning. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197577479.003.0006
239. Persinger, M. A. (1989). Geophysical Variables and Behavior: LV. Predicting the Details of Visitor Experiences and the Personality of Experients: The Temporal Lobe Factor. Perceptual and Motor Skills. https://doi.org/10.2466/pms.1989.68.1.55
240. Peña, M. A. M. (2013). Síndrome de sobreentrenamiento. IATREIA.
241. Peña, M. D. M. J. D. L., Alonso, R. C., Suárez, A. M., Caicoya, A. G., Alfonso, A. F., & Vega, V. M. D. (2018). Imagen en epilepsia. Seram.
242. Peña, M. D. M. J. D. L., Alonso, R. C., Suárez, A. M., Caicoya, A. G., Alfonso, A. F., & Vega, V. M. D. (2018). Imagen en epilepsia:: más allá de la etiología.. Seram.
243. Pisón, J. L., Delgado, A. F. B., Mallada, P. L., Romero, M. R. C., Diago, R. C. D., & Segura, J. L. P. (2004). Síndrome opercular anterior como manifestación de estado epiléptico no convulsivo. Revista de Neurología. https://doi.org/10.33588/rn.3810.2004010
244. Pontillo, M., Armando, M., Coletti, M., Santonastaso, O., & Vicari, S. (2016). Schizofrenia ad esordio in età evolutiva: aspetti clinici e interventi possibili. QUADERNI DI PSICOTERAPIA COGNITIVA. https://doi.org/10.3280/qpc2016-039003
245. Pradeep, V. A. J. (2013). Study on Neurological Soft Signs in patients with ObsessiveCompulsive Disorder..
246. Prager, L. M. (2009). Depression and Suicide in Children and Adolescents. Pediatrics in Review. https://doi.org/10.1542/pir.30.6.199
247. Praško, J., Raszka, M., & Pastucha, P. (2009). Dissociative Disorders - Clinical Manifestation and Management. European Psychiatry. https://doi.org/10.1016/s0924-9338(09)70376-1
248. Putra, H. G. S. A. (2015). GANGGUAN AFEKTIF BIPOLAR MANIA DENGAN PSIKOTIK: SEBUAH LAPORAN KASUS. DOAJ (DOAJ: Directory of Open Access Journals).
249. Pérez, P. S. (2015). El déficit cognitivo en el síndrome de fatiga crónica: factores asociados y evolución.
250. Rachmani, S., & Mayasari, D. (2017). Kombinasi Farmakoterapi dan Psikoterapi Pada Pengobatan Episode Depresif Sedang Dengan Gejala Somatis. Jurnal Medula.
251. Raj, S., & Gale, S. A. (2017). [P4–173]: NEW ONSET PSYCHOTIC SYMPTOMS AS THE INITIAL PRESENTATION OF EARLY ONSET ALZHEIMER'S DISEASE. Alzheimer s & Dementia. https://doi.org/10.1016/j.jalz.2017.06.2040
252. Rao, T. S., & Kumar, M. A. (2008). Agenda for specialty section in addiction medicine. Indian Journal of Psychiatry. https://doi.org/10.4103/0019-5545.44741
253. Remschmidt, H., Schulz, E., Martín, M., Fleischhaker, C., & Trott, G.-E. (1994). [Early manifestations of schizophrenic psychoses].. PubMed.
254. Riddle, M. A., King, R. A., Hardin, M. T., Scahill, L. D., Ort, S. I., Chappell, P., Rasmusson, A. M., & Leckman, J. F. (1990). Behavioral Side Effects of Fluoxetine in Children and Adolescents. Journal of Child and Adolescent Psychopharmacology. https://doi.org/10.1089/cap.1990.1.193
255. Riley, M. A., Ahmed, S., & Locke, A. (2016). Common Questions About Oppositional Defiant Disorder.. PubMed.
256. Rinkel, M., Deshon, H. J., Hyde, R. W., & Solomon, H. C. (1952). EXPERIMENTAL SCHIZOPHRENIA-LIKE SYMPTOMS. American Journal of Psychiatry. https://doi.org/10.1176/ajp.108.8.572
257. Rm, S. (1990). [Causalgia in neurologic expert assessment].. PubMed.
258. Roberts, A. R., & Yeager, K. R. (2009). Indicators of a Crisis-Prone Person. https://doi.org/10.1093/oso/9780195382907.003.0004
259. Roberts, A. R., & Yeager, K. R. (2009). Psychophysiological Reactions to a Crisis. https://doi.org/10.1093/oso/9780195382907.003.0007
260. Roberts, A. R., & Yeager, K. R. (2009). Stress Symptomatology and the General Adaptation Syndrome. https://doi.org/10.1093/oso/9780195382907.003.0008
261. Roberts, J., Stewart, C., & Kearney, S. (2016). Management of the behavioural manifestations of Hunter syndrome. British Journal of Nursing. https://doi.org/10.12968/bjon.2016.25.1.22
262. Rojas, S. L., & Widiger, T. A. (2018). Personality Disorders. Oxford University Press eBooks. https://doi.org/10.1093/med-psych/9780190492243.003.0021
263. Roncero, C., & Casas, M. (2004). Trastornos de ansiedad en patología dual.
264. Rosa, E. F., & Rustiaty, N. (2018). Affective Disorders in The Elderly: The Risk of Sleep Disorders. International Journal of Public Health Science (IJPHS). https://doi.org/10.11591/ijphs.v7i1.9960
265. Rosli, A. (2017). Antidepressant Activity of Spirulina Platensis in Models of Depression. Psychology and Mental Health Care. https://doi.org/10.31579/2637-8892/003
266. Rowe, P. C., Underhill, R., Friedman, K. J., Gurwitt, A., Medow, M. S., Schwartz, M., Speight, N., Stewart, J. M., Vallings, R., & Rowe, K. S. (2017). Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Diagnosis and Management in Young People: A Primer. Frontiers in Pediatrics. https://doi.org/10.3389/fped.2017.00121
267. Rudolf, G. A. E. (2000). Diagnostische und therapeutische Maßnahmen bei einzelnen schizophrenen Syndromen und in bestimmten krankheitsbedingten Situationen. Deutscher Universitätsverlag eBooks. https://doi.org/10.1007/978-3-322-85177-2_7
268. Rus, S. S., Solis, M., Rodríguez, L. S., & Suárez-Gómez, M. (2021). Depressive disorder in childhood: The importance of an early diagnosis for a functional recovery. Specific symptoms and treatment in an 8-years old patient with depression. European Psychiatry. https://doi.org/10.1192/j.eurpsy.2021.891
269. Ríos, C. G., Sánchez, M. V., Campos, M. L. P., Lozano, C. F., & Montañés, P. M. (2021). Mitos y realidades sobre la enuresis en pediatría.. Revista Sanitaria de Investigación.
270. Sahakian, B. J., & Morein‐Zamir, S. (2011). Depression and resilience: insights from cognitive, neuroimaging, and psychopharmacological studies. Oxford University Press eBooks. https://doi.org/10.1093/acprof:oso/9780199600434.003.0023
271. Sahu, S., Chaudhury, S., Pathak, V., Singh, I., Mujawar, S., Arya, A., Mishra, A., Sharma, N., & Garg, G. (2021). Diverse psychiatric presentation associated with child sexual abuse. Industrial Psychiatry Journal. https://doi.org/10.4103/0972-6748.328866
272. Salokangas, R. K. R., & McGlashan, T. H. (2008). Early detection and intervention of psychosis. A review. Nordic Journal of Psychiatry. https://doi.org/10.1080/08039480801984008
273. Sass, L. A., Borda, J. P., Madeira, L., Pienkos, E., & Nelson, B. (2018). Varieties of Self Disorder: A Bio-Pheno-Social Model of Schizophrenia. Schizophrenia Bulletin. https://doi.org/10.1093/schbul/sby001
274. Sawarkar, A., Shambharkar, R., Shambharkar, M., Khandar, J., Sakharwade, P., & Kasturkar, P. (2021). Case Report on Acute Transient Psychotic Disorder. Journal of Pharmaceutical Research International. https://doi.org/10.9734/jpri/2021/v33i45b32783
275. Scarmeas, N., Honig, L. S., Choi, H., Cantero, J., Brandt, J., Blacker, D., Albert, M., Amatniek, J., Marder, K., Bell, K. L., Hauser, W. A., & Stern, Y. (2009). Seizures in Alzheimer Disease. Archives of Neurology. https://doi.org/10.1001/archneurol.2009.130
276. Schildkrout, B. (2014). Delirium. https://doi.org/10.1002/9781394260447.ch2
277. Schildkrout, B. (2014). Disease #4: Alzheimer's Disease. https://doi.org/10.1002/9781394260447.ch32
278. Schildkrout, B. (2014). Disease #53: Postconcussion Syndrome. https://doi.org/10.1002/9781394260447.ch81
279. Schildkrout, B. (2014). Hallucinations. https://doi.org/10.1002/9781394260447.ch8
280. Schultze‐Lutter, F. (2016). First Signs of Emerging Psychosis. Key issues in mental health (Online)/Key issues in mental health (Print). https://doi.org/10.1159/000440912
281. Schultze‐Lutter, F., & Theodoridou, A. (2017). The concept of basic symptoms: its scientific and clinical relevance. World Psychiatry. https://doi.org/10.1002/wps.20404
282. Schwartz, B. (1990). Early information processing in schizophrenia.. PubMed.
283. Seliger, G. M., LeFever, F. F., Lukas, R. G., Chen, J., Schwartz, S., Codeghini, L., & Abrams, G. (1991). Word deafness in head injury: Implications for coma assessment and rehabilitation. Brain Injury. https://doi.org/10.3109/02699059108998511
284. Selwood, L. (2015). Adherence in schizophrenia. Mental Health Matters.
285. Serdyuk, O., Drobizhev, М. Y., & Retyunsky, K. (2011). ICD-10 and the clinical features of depressions: data of the CIRCADIAN-I program. Neurology neuropsychiatry Psychosomatics. https://doi.org/10.14412/2074-2711-2011-167
286. Sharma, H. (2009). Treatment of Tardive Dyskinesia by tetrabenazine, clonazepam and vitamin E. Indian Journal of Psychiatry. https://doi.org/10.4103/0019-5545.49466
287. Sharma, S. (2021). Limited speech outside the home in a young girl who speaks normally at home. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197577479.003.0010
288. Siclari, F. (2024). Consciousness in Non-REM parasomnia episodes. bioRxiv (Cold Spring Harbor Laboratory). https://doi.org/10.1101/2024.06.02.597000
289. Siclari, F. (2024). Consciousness in non‐<scp>REM</scp>‐parasomnia episodes. Journal of Sleep Research. https://doi.org/10.1111/jsr.14275
290. Silva, L. I. F. D., Souza, L. M., Gonzales, M. F., & Jurado, S. R. (2015). SLEEP DISORDERS IN CHILDHOOD. Simpósio Internacional de Neurociências da Grande Dourados.
291. Silva, M. F. D., Marau, J., Duque, T., Lobarinhas, M. J., Manuel, C., & Porfírio, M. F. (2024). PSYCHOGENIC NON-EPILEPTIC SEIZURES AND BORDERLINE PERSONALITY DISORDER IN AN ADOLESCENT GIRL. Psicologia e Saúde em Debate. https://doi.org/10.22289/2446-922x.v10a2a53
292. Singh, R., & Chaudhury, S. (2009). Hyponatremia-induced psychosis in an industrial setting. Industrial Psychiatry Journal. https://doi.org/10.4103/0972-6748.62277
293. Singh, S. (2015). Mental health in infancy. International Journal of Clinical & Medical Imaging. https://doi.org/10.4172/2376-0249.1000393
294. Singh, S., & Adam, P. (2015). What can be done to slow progression of Alzheimer's disease in the elderly?. Evidence-Based Practice. https://doi.org/10.1097/01.ebp.0000540940.04507.0e
295. Sinha, R., & Singh, S. (2021). Clinical and Electroencephalogram Correlation of Self-Limited Epilepsy with Autonomic Seizures. Indian Pediatrics Case Reports. https://doi.org/10.4103/ipcares.ipcares_287_21
296. Smid, G. E., Lenferink, L. I. M., Keijser, J. D., & Boelen, P. A. (2017). Ambiguous loss in relatives of missing or disappeared persons.
297. Sommer, I. E., & Arango, C. (2017). Moving interventions from after to before diagnosis. World Psychiatry. https://doi.org/10.1002/wps.20454
298. Sood, M., & Kattimani, S. (2008). Childhood Onset Schizophrenia: Clinical Features, Course and Outcome. Journal of Indian Association for Child and Adolescent Mental Health. https://doi.org/10.1177/0973134220080202
299. Sołtys, K., Bidzan, L., Turczyński, J., & Łapin, J. (2005). [Assessment of early traumatic life events influence on intensity and frequency of symptoms in patients aged 50 years and over].. PubMed.
300. Spies, J. (2001). 8: Cranial and peripheral neuropathies. The Medical Journal of Australia. https://doi.org/10.5694/j.1326-5377.2001.tb143451.x
301. Staniloiu, A., Borsutzky, S., & Markowitsch, H. J. (2010). P01-315 - Dissociative Memory Impairments and Immigration. European Psychiatry. https://doi.org/10.1016/s0924-9338(10)70523-x
302. Stecher, S. (2018). Understanding Disorders of Mood exploring the differences between Disorders of Thought and Mood.
303. Stone, J., Pal, S., Blackburn, D., Reuber, M., Thekkumpurath, P., & Carson, A. (2015). Functional (Psychogenic) Cognitive Disorders: A Perspective from the Neurology Clinic. Journal of Alzheimer s Disease. https://doi.org/10.3233/jad-150430
304. Stoohs, R., Guilleminault, C., & Quera-Salva, M. (1992). Sleep-related obstructive and nonobstructive apneas and neurologic disorders.. PubMed.
305. Stringaris, A., & Krieger, F. (2013). Bipolar disorder and disruptive mood dysregulation in children and adolescents: assessment, diagnosis and treatment. Evidence-Based Mental Health. https://doi.org/10.1136/eb-2013-101400
306. Stringer, S., Nieman, D. H., Kahn, R. S., & Derks, E. M. (2015). Genome-wide association analysis in schizophrenia. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9781107337459.010
307. Stubbe, D. (2007). Child and adolescent psychiatry : a practical guide. Lippincott Williams & Wilkins eBooks.
308. Stubbs, B. (2011). Displays of inappropriate sexual behaviour by patients with progressive cognitive impairment: the forgotten form of challenging behaviour?. Journal of Psychiatric and Mental Health Nursing. https://doi.org/10.1111/j.1365-2850.2011.01709.x
309. Stumpf, B. P., & Rocha, F. L. (2010). Síndrome de Diógenes. Jornal Brasileiro de Psiquiatria. https://doi.org/10.1590/s0047-20852010000200012
310. Sturm, H., Fernell, E., & Gillberg, C. (2004). Autism spectrum disorders in children with normal intellectual levels: associated impairments and subgroups. Developmental Medicine & Child Neurology. https://doi.org/10.1017/s0012162204000738
311. Sturm, H., Fernell, E., & Gillberg, C. (2004). Autism spectrum disorders in children with normal intellectual levels: associated impairments and subgroups. Developmental Medicine & Child Neurology. https://doi.org/10.1111/j.1469-8749.2004.tb00503.x
312. Sung, H. C., & Chang, A. B. (2010). The effectiveness of preferred or familiar music listening on behavioural and psychological symptoms of institutionalised older adults with dementia: a systematic review. JBI Library of Systematic Reviews. https://doi.org/10.11124/jbisrir-2010-726
313. Sung, H. C., & Chang, A. B. (2010). The effectiveness of preferred or familiar music listening on behavioural and psychological symptoms of institutionalised older adults with dementia: a systematic review. The JBI Database of Systematic Reviews and Implementation Reports. https://doi.org/10.11124/01938924-201008341-00020
314. Szaffarczyk, S., Lapierre, P., Danel, T., Cottencin, O., & Pins, D. (2015). Étude du sentiment de familiarité dans l’alcoolo-dépendance : une hyperfamiliarité aux visages. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2015.09.199
315. Tabbane, K., Triki, R., Hajeri, S., Johnson, I., & Chérif, W. (2012). P-1319 - Prodromal symptoms of schizophrenia: a retrospective tunisian study. European Psychiatry. https://doi.org/10.1016/s0924-9338(12)75486-x
316. Tamminga, C. A., Buchanan, R. W., & Gold, J. M. (1998). The role of negative symptoms and cognitive dysfunction in schizophrenia outcome. International Clinical Psychopharmacology. https://doi.org/10.1097/00004850-199803003-00004
317. Tantam, D. (1988). Lifelong Eccentricity and Social Isolation. The British Journal of Psychiatry. https://doi.org/10.1192/bjp.153.6.783
318. Tatsuzawa, Y., Ono, Y., Takahashi, T., Yoshino, A., & Nomura, S. (2011). Case of isolated adrenocorticotropic hormone deficiency mimicking major depressive disorder. Psychiatry and Clinical Neurosciences. https://doi.org/10.1111/j.1440-1819.2011.02207.x
319. Taylor, H. G. (2010). Academic performance and learning disabilities. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511712166.017
320. Thomas, S., Zachariah, R. A., & Mathew, N. M. (2021). Perinatal Mental Health Problems –What Midwives and Nurses can do?. International Journal of Psychiatric Nursing. https://doi.org/10.37506/ijpn.v7i1.13967
321. Tiryaki, A., Özkorumak, E., & Ak, İ. (2009). Deficit syndrome in schizophrenia. Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology.
322. Toro, V. D., Aedo, K., & Urrejola, P. (2021). Trastorno de Evitación y Restricción de la Ingesta de Alimentos (ARFID): Lo que el pediatra debe saber. Andes pediatrica. https://doi.org/10.32641/andespediatr.v92i2.2794
323. Trahan, M. A., Kahng, S., Donaldson, J. M., & McNabney, M. (2013). “Just Make it Stop”: A Case Report of Excessive Crying in an Individual with Dementia. Journal of the American Geriatrics Society. https://doi.org/10.1111/jgs.12339
324. Travers, C., MacAndrew, M., Hines, S., O’Reilly, M., Fielding, E., Beattie, E., & Brooks, D. (2015). The effectiveness of meaningful occupation interventions for people living with dementia in residential aged care: a systematic review protocol. The JBI Database of Systematic Reviews and Implementation Reports. https://doi.org/10.11124/01938924-201513040-00008
325. Travers, C., MacAndrew, M., Hines, S., O’Reilly, M., Fielding, E., Beattie, E., & Brooks, D. (2015). The effectiveness of meaningful occupation interventions for people living with dementia in residential aged care: a systematic review protocol. The JBI Database of Systematic Reviews and Implementation Reports. https://doi.org/10.11124/jbisrir-2015-2058
326. Tso, I. F., Chun, J., & Deldin, P. J. (2010). Schizoaffective Disorder. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy0818
327. Uehara, T., Ishige, Y., & Su, M. (2011). Dissociative Tendency, Anger Expression, and Frontal Activation During a Verbal Fluency Task. InTech eBooks. https://doi.org/10.5772/26312
328. Usami, S., & Nishio, S. (2018). Nonsyndromic Hearing Loss and Deafness, Mitochondrial.
329. Valdéz, P. (2018). Homeostatic and circadian regulation of cognitive performance. Biological Rhythm Research. https://doi.org/10.1080/09291016.2018.1491271
330. Vallejo, J. D. O. (2001). Detecció precoç de la depressió. Revista de la Reial Acadèmia de Medicina de Catalunya.
331. Velleman, S. L., & Mervis, C. Β. (2011). Children With 7q11.23 Duplication Syndrome: Speech, Language, Cognitive, and Behavioral Characteristics and Their Implications for Intervention. Perspectives on Language Learning and Education. https://doi.org/10.1044/lle18.3.108
332. Verma, S., & Agrawal, R. (2021). The lasting effects of childhood trauma. Current psychiatry. https://doi.org/10.12788/cp.0101
333. Verma, S., & Kushwaha, S. (2016). Intelligence and Attention Deficit Hyperactivity Disorder. JOURNAL OF PSYCHOSOCIAL RESEARCH.
334. Vilibić, M., Jukić, V., Vidović, A., & Brečić, P. (2013). Cobalamin deficiency manifested with seizures, mood oscillations, psychotic features and reversible dementia in the absence of typical neurologic and hematologic signs and symptoms: a case report.. PubMed.
335. Vn, M. (1989). [Clinical aspects of paroxysmal states in children with depression].. PubMed.
336. Walther, S. (2018). Motorische Auffälligkeiten bei Schizophrenie: Effekte auf Kommunikation und mögliche Therapieoptionen.
337. Wichaidit, B. T., Rask, C. U., & Østergaard, J. R. (2014). [Diagnosing functional seizures in children and adolescents].. Research Portal Denmark.
338. Widiger, T. A., & Oltmanns, J. R. (2017). Neuroticism is a fundamental domain of personality with enormous public health implications. World Psychiatry. https://doi.org/10.1002/wps.20411
339. Wieling, W., Thijs, R. D., Dijk, N. V., Wilde, A. A., Benditt, D. G., & Dijk, J. G. V. (2009). Symptoms and signs of syncope: a review of the link between physiology and clinical clues. Brain. https://doi.org/10.1093/brain/awp179
340. Wing, L. (2005). Autistic Spectrum Disorders. PsycEXTRA Dataset. https://doi.org/10.1037/e619152012-001
341. Winter, A., & Buhlmann, U. (2013). Spieglein, Spieglein an der Wand … Klinische Charakteristika der körperdysmorphen Störung. Zeitschrift für Psychiatrie Psychologie und Psychotherapie. https://doi.org/10.1024/1661-4747/a000155
342. Wissow, L. S. (2021). Anxiety and Trauma-Related Distress. Pediatric Care Online. https://doi.org/10.1542/aap.ppcqr.396464
343. Woo, S., & Keatinge, C. (2016). Neurodevelopmental Disorders I: Autism Spectrum Disorder. https://doi.org/10.1002/9781394259472.ch4
344. Yu, Y., & Gong, S.-P. (2008). Multiple organ supportive therapy for obstetric multiple organ dysfunction syndrome. https://doi.org/10.3321/j.issn:0376-2491.2008.11.003
345. Yung, A. R. (2011). Risk, Disorder and Diagnosis. Australian & New Zealand Journal of Psychiatry. https://doi.org/10.3109/00048674.2011.614926
346. Zamorski, M. A., & Ward, R. (2000). Social Anxiety Disorder: Common, Disabling, and Treatable. The Journal of the American Board of Family Medicine. https://doi.org/10.3122/15572625-13-4-251
347. Zellner, H., Baumann, M., Zotter, S., Albrecht, U., Baumgartner, S., Gedik, A. H., Zeiner, F., Egger, S., Heinz-Erian, E., Kößler, M., Lechner, C., Zschocke, A., & Haberlandt, E. (2016). Landau-Kleffner Syndrome (Epileptic Aphasia). Neuropediatrics. https://doi.org/10.1055/s-0036-1583627
348. Zisook, S., Schneider, D., & Shuchter, S. R. (1990). Anxiety and bereavement.. PubMed.
349. Álvarez, B., Dahlitz, M., Vignau, J., & Parkes, J. D. (1992). The delayed sleep phase syndrome: clinical and investigative findings in 14 subjects.. Journal of Neurology Neurosurgery & Psychiatry. https://doi.org/10.1136/jnnp.55.8.665
350. Çelik, A. S., & Pasinlioğlu, T. (2013). KLİMAKTERİK DÖNEMDE YAŞANAN SEMPTOMLAR VE HEMŞİRENİN ROLÜ.